<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Antioxid Redox Signal</journal-id>
<journal-id journal-id-type="iso-abbrev">Antioxid. Redox Signal</journal-id>
<journal-id journal-id-type="publisher-id">ars</journal-id>
<journal-title-group>
<journal-title>Antioxidants &amp; Redox Signaling</journal-title>
</journal-title-group>
<issn pub-type="ppub">1523-0864</issn>
<issn pub-type="epub">1557-7716</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc.</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26583264</article-id>
<article-id pub-id-type="pmc">4657512</article-id>
<article-id pub-id-type="publisher-id">10.1089/ars.2015.6433</article-id>
<article-id pub-id-type="doi">10.1089/ars.2015.6433</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Forum Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Casas</surname>
<given-names>Ana I.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dao</surname>
<given-names>V. Thao-Vi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daiber</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maghzal</surname>
<given-names>Ghassan J.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Lisa</surname>
<given-names>Fabio</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4,</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaludercic</surname>
<given-names>Nina</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leach</surname>
<given-names>Sonia</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cuadrado</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaquet</surname>
<given-names>Vincent</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seredenina</surname>
<given-names>Tamara</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krause</surname>
<given-names>Karl H.</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López</surname>
<given-names>Manuela G.</given-names>
</name>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stocker</surname>
<given-names>Roland</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ghezzi</surname>
<given-names>Pietro</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Schmidt</surname>
<given-names>Harald H.H.W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><label><sup>1</sup></label>Department of Pharmacology, Cardiovascular Research Institute Maastricht (CARIM), <institution>Maastricht University</institution>, Maastricht, <country>the Netherlands</country>.</aff>
<aff id="aff2"><label><sup>2</sup></label>2nd Medical Department, Molecular Cardiology, <institution>University Medical Center</institution>, Mainz, <country>Germany</country>.</aff>
<aff id="aff3"><label><sup>3</sup></label>Victor Chang Cardiac Research Institute, and School of Medical Sciences, <institution>University of New South Wales</institution>, Sydney, New South Wales, <country>Australia</country>.</aff>
<aff id="aff4"><label><sup>4</sup></label>Department of Biomedical Sciences, <institution>University of Padova</institution>, <country>Italy</country>.</aff>
<aff id="aff5"><label><sup>5</sup></label><institution>Neuroscience Institute</institution>, CNR, Padova, <country>Italy</country>.</aff>
<aff id="aff6"><label><sup>6</sup></label><institution>Brighton and Sussex Medical School</institution>, Falmer, <country>United Kingdom</country>.</aff>
<aff id="aff7"><label><sup>7</sup></label>Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ISCIII, Instituto de Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry, Faculty of Medicine, <institution>Autonomous University of Madrid</institution>, Madrid, <country>Spain</country>.</aff>
<aff id="aff8"><label><sup>8</sup></label>Department of Pathology and Immunology, Medical School, <institution>University of Geneva</institution>, Geneva, <country>Switzerland</country>.</aff>
<aff id="aff9"><label><sup>9</sup></label>Teofilo Hernando Institute, Department of Pharmacology, <institution>Faculty of Medicine. Autonomous University of Madrid</institution>, Madrid, <country>Spain</country>.</aff>
</contrib-group>
<author-notes>
<corresp>
<addr-line>Address correspondence to:</addr-line>
<addr-line>
<italic>Ana I. Casas</italic>
</addr-line>
<addr-line>
<italic>Department of Pharmacology</italic>
</addr-line>
<addr-line>
<italic>Cardiovascular Research</italic>
</addr-line>
<addr-line>
<italic>Institute Maastricht (CARIM)</italic>
</addr-line>
<institution>
<italic>Maastricht University</italic>
</institution>
<addr-line>
<italic>Maastricht</italic>
</addr-line>
<country>The Netherlands</country>
<break></break>
<italic>E-mail:</italic>
<email xlink:href="mailto:a.casasguijarro@maastrichtuniversity.nl">a.casasguijarro@maastrichtuniversity.nl</email>
</corresp>
<corresp>
<addr-line>
<italic>Dr. Harald H. H. W. Schmidt</italic>
</addr-line>
<addr-line>
<italic>Department of Pharmacology</italic>
</addr-line>
<addr-line>
<italic>Cardiovascular Research</italic>
</addr-line>
<addr-line>
<italic>Institute Maastricht (CARIM)</italic>
</addr-line>
<institution>
<italic>Maastricht University</italic>
</institution>
<addr-line>
<italic>Maastricht</italic>
</addr-line>
<country>The Netherlands</country>
<break></break>
<italic>E-mail:</italic>
<email xlink:href="mailto:h.schmidt@maastrichtuniversity.nl">h.schmidt@maastrichtuniversity.nl</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>10</day>
<month>11</month>
<year>2015</year>
<!--string-date: November 10, 2015-->
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>11</month>
<year>2015</year>
<!--string-date: November 10, 2015-->
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
<volume>23</volume>
<issue>14</issue>
<fpage>1171</fpage>
<lpage>1185</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>6</month>
<year>2015</year>
<!--string-date: Date of first submission to ARS Central, June 30, 2015-->
</date>
<date date-type="rev-recd">
<day>06</day>
<month>10</month>
<year>2015</year>
<!--string-date: date of final revised submission, October 6, 2015-->
</date>
<date date-type="accepted">
<day>06</day>
<month>10</month>
<year>2015</year>
<!--string-date: date of acceptance, October 6, 2015-->
</date>
</history>
<permissions>
<copyright-statement>© Casas <italic>et al.</italic> 2015; Published by Mary Ann Liebert, Inc.</copyright-statement>
<copyright-year>2015</copyright-year>
<license license-type="open-access">
<license-p>This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="ars.2015.6433.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p><bold><italic>Significance:</italic></bold> Enhanced levels of reactive oxygen species (ROS) have been associated with different disease states. Most attempts to validate and exploit these associations by chronic antioxidant therapies have provided disappointing results. Hence, the clinical relevance of ROS is still largely unclear. <bold><italic>Recent Advances:</italic></bold> We are now beginning to understand the reasons for these failures, which reside in the many important physiological roles of ROS in cell signaling. To exploit ROS therapeutically, it would be essential to define and treat the disease-relevant ROS at the right moment and leave physiological ROS formation intact. This breakthrough seems now within reach. <bold><italic>Critical Issues:</italic></bold> Rather than antioxidants, a new generation of protein targets for classical pharmacological agents includes ROS-forming or toxifying enzymes or proteins that are oxidatively damaged and can be functionally repaired. <bold><italic>Future Directions:</italic></bold> Linking these target proteins in future to specific disease states and providing in each case proof of principle will be essential for translating the oxidative stress concept into the clinic. <italic>Antioxid. Redox Signal.</italic> 23, 1171–1185.</p>
</abstract>
<counts>
<fig-count count="5"></fig-count>
<table-count count="3"></table-count>
<equation-count count="4"></equation-count>
<ref-count count="159"></ref-count>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s001" sec-type="intro">
<title>Introduction</title>
<p>R<sc>eactive oxygen species (ROS)</sc> regulate several essential physiological processes (<xref ref-type="bibr" rid="B63">63</xref>), including cell proliferation and differentiation, vascular tone, the innate immune response, and inflammation (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B63">63</xref>). Conversely, aberrant ROS formation may trigger disease either by reaching concentrations that exceed cellular antioxidant defense mechanisms or by more subtle changes, such as ROS production in inappropriate cellular compartments (<italic>e.g.</italic>, a subcellular localization that physiologically does not produce ROS) or a shift in the type of ROS being formed (<italic>e.g.</italic>, superoxide instead of hydrogen peroxide) (<xref ref-type="bibr" rid="B32">32</xref>). This may then alone or in combination with other factors contribute to various cardiovascular, (<xref ref-type="bibr" rid="B45">45</xref>) neurological, or metabolic pathologies (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B147">147</xref>) or cancer (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B137">137</xref>), all diseases with high socioeconomical impact and medical need (<xref ref-type="bibr" rid="B77">77</xref>).</p>
<p>Different pharmacological strategies have been pursued to prevent or restore such supposedly systemic redox imbalances and to improve disease outcomes, typically with antioxidant drugs or vitamins. However, intervention trials with small molecules, especially antioxidants, have been mostly ineffective (<xref ref-type="bibr" rid="B78">78</xref>) or even harmful (<xref ref-type="bibr" rid="B122">122</xref>). Hence, no direct antioxidant approach is currently part of any evidence guideline and the oxidative stress hypothesis still awaits validation in humans.</p>
<p>One crucial reason for these failures may reside in the dichotomy between disease-triggering and beneficial ROS and differences in this between humans and animal models of disease (<xref ref-type="bibr" rid="B132">132</xref>). To target redox-dependent diseases safely and effectively, physiological ROS sources that are relevant for signaling need to remain untouched, while disease-triggering ROS should be effectively reduced.</p>
<p>Instead of antioxidants, a more recent and innovative approach uses pharmacological agents that selectively suppress the activity of ROS-forming or toxifying enzymes (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>) whose activity or expression is increased under pathological conditions. These include the ROS generators, such as nitric oxide synthase (NOS), monoamine oxidase (MAO), xanthine oxidase (XO), and NADPH oxidase (NOX), or the ROS toxifier, myeloperoxidase (MPO) (<xref ref-type="fig" rid="f1">Fig. 1</xref>). In addition, we will review a third and possibly synergistic strategy to functionally repair proteins that have been damaged by ROS (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology). It is also possible to reinforce redox homeostasis by targeting the transcription factor Nrf2, a master regulator of the antioxidant control (<xref ref-type="bibr" rid="B122">122</xref>). We jointly review these ROS-based interventions of high clinical potential and place them into context. However, all targets included in this review are described at different levels based on their clinical relevance and maturity in drug development.</p>
<fig fig-type="figure" id="f1" orientation="portrait" position="float">
<label>
<bold>FIG. 1.</bold>
</label>
<caption>
<p><bold>Sources and targets of reactive oxygen species.</bold> Largely beneficial enzymes or enzymes that downregulate cyclic GMP (cGMP) signaling include nitric oxide synthase, Fe(II) heme-containing guanylate cyclase; PKG, cGMP-dependent protein kinase; largely detrimental or cGMP downregulating enzymes, include uc-NOS, uncoupled, NOS apo-sGC converted from sGC; PDE, phosphodiesterases; NOX, NADPH oxidase; MPO, myeloperoxidase; Mito, mitochondria; LPO, lipid peroxidase; XO, xanthine oxidase converted from XD, xanthine dehydrogenase; MAO, monoamine oxidase. Antioxidant proteins include SOD, superoxide dismutase; Nrf2, nuclear factor (erythroid-derived 2)-like 2; ARE, antioxidant response element; T/Prx, Thio/Peroxyredoxin. Drugs are depicted next to <italic>oblique lines</italic> (<italic>arrows</italic> indicate activation; blocks, inhibition) either in <italic>bold</italic> (in clinical use: PDEi, PDE inhibitors; sGCs, sGC stimulators; NOd, NO donors; NOSr, NOS recoupling agents; MAOi, monoamine oxidase inhibitors; XODi, XOD inhibitors) or italics (in pre/clinical development: MPOi, MPO inhibitors; sGCa, sGC activators; NOSi, NOS inhibitors; Nrf2a, Nrf2 agonists; NOXi, NOX inhibitors). Proteins in the lower part indicate targets and biomarkers of cGMP and reactive oxygen species signaling: PPase, phosphatases; TRP, transient receptor potential channels; Tyr/Trp-NO<sub>2</sub><sup>−</sup>, tyrosine or tryptophan-nitrated proteins; Tyr-Cl, tyrosine-chlorinated proteins (<xref ref-type="bibr" rid="B156">38a</xref>).</p>
</caption>
<graphic xlink:href="fig-1"></graphic>
</fig>
<p>Comparison between pharmacological inhibition of enzymes and changes observed in knockout (KO) animals is detailed in the review. In most cases, a KO represents a <italic>de novo</italic> deficiency possibly leading to adaptive responses. However, most drug interventions are initiated after onset of the disease (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology). Therefore, although both approaches are not always comparable, they are needed for targeting validation.</p>
<sec id="s002">
<title>Physiology of ROS</title>
<p>While the existence of endogenous antioxidant enzymes (<italic>i.e.</italic>, superoxide dismutase, glutathione peroxidase, catalase) suggests that the capacity to eliminate ROS is of evolutionary benefit (<xref ref-type="bibr" rid="B121">121</xref>), evidence that ROS fulfill equally essential physiological functions stems from the existence of the NOX enzyme family that has no other known function than to produce ROS (<xref ref-type="bibr" rid="B72">72</xref>). <xref ref-type="table" rid="T1">Table 1</xref> lists the major enzymatic sources of ROS, ROS toxifiers, and their biological effects. Importantly, these physiological effects, which can be ascribed to a specific ROS source or toxifying enzyme, need to be kept in mind as potential side effects of enzyme inhibitors during chronic therapy.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label><sc>Table</sc> 1.</label>
<caption>
<p>
<sc>Physiological Role of Reactive Oxygen Species Sources and Reactive Oxygen Species Toxifiers</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Enzyme</italic>
</th>
<th align="center">
<italic>Function</italic>
</th>
<th align="center">
<italic>Potential side effect</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">NOX1</td>
<td align="left">GI epithelial immune defense</td>
<td align="left">GI infections</td>
</tr>
<tr>
<td align="left">NOX2</td>
<td align="left">Innate immune response</td>
<td align="left">CGD, immune suppression</td>
</tr>
<tr>
<td align="left">NOX3</td>
<td align="left">Otoconia formation</td>
<td align="left">Balance problems</td>
</tr>
<tr>
<td align="left">NOX4</td>
<td align="left">Angiogenesis</td>
<td align="left">Preconditioning, increased sensitivity to ischemic damage</td>
</tr>
<tr>
<td align="left">NOX5</td>
<td align="left">Sperm motility</td>
<td align="left">Male infertility, immunosuppression</td>
</tr>
<tr>
<td align="left">DUOX</td>
<td align="left">Thyroid hormone formation</td>
<td align="left">Thyroid suppression</td>
</tr>
<tr>
<td align="left">MPO</td>
<td align="left">Immune defense</td>
<td align="left">Immune suppression</td>
</tr>
<tr>
<td align="left">XO</td>
<td align="left">Catabolism of purines</td>
<td align="left">Mild</td>
</tr>
<tr>
<td align="left">MAO</td>
<td align="left">Breakdown of neurotransmitters</td>
<td align="left">GI diseases and skin reaction</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf1">
<p>Potential side effects of drugs targeting these enzymes.</p>
</fn>
<fn id="tf2">
<p>CGD, chronic granulomatous disease; DUOX, dual oxidase; GI, gastrointestinal; MAO, monoamine oxidase; MPO, myeloperoxidase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; XO, xanthine oxidase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s003">
<title>From chemical antioxidants to defined enzyme targets</title>
<p>Antioxidants may have a benefit in acute parenteral treatment, but evidence in chronic therapy is lacking (<xref ref-type="bibr" rid="B132">132</xref>). One conceptual problem with the antioxidant approach is the fact that it overlooks that ROS also may have beneficial effects. Thus, scavenging ROS systemically may interfere with physiological as well as with pathological processes. However, three alternative approaches to ROS scavenging have been described, including the targeting of the relevant sources of ROS, ROS toxifiers, or repairing previously oxidized proteins (<italic>e.g.</italic>, oxidized soluble guanylate cyclase [sGC] or endothelial nitric oxide synthase [eNOS]). In fact, targeting disease-relevant enzymatic sources of ROS is one of the most promising options. In this strategy, NOXs are a major target. All other enzymes generate ROS together with other products (<italic>e.g.</italic>, MAO) or start to form ROS as a result of a biochemical accident induced by their proteolytic or oxidative modifications. (<xref ref-type="bibr" rid="B159">125a</xref>) The latter include XO (<xref ref-type="bibr" rid="B57">57</xref>), uncoupled endothelial NOS (uc-eNOS from eNOS) (<xref ref-type="bibr" rid="B95">95</xref>), and several mitochondrial enzymes, particularly respiratory chain complexes. Another important category of enzyme targets includes ROS toxifiers (<xref ref-type="bibr" rid="B70">70</xref>). We define them as enzymes that convert relatively nontoxic ROS such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to more reactive species. A typical example is MPO, which converts H<sub>2</sub>O<sub>2</sub> into hypochlorous acid (HOCl) (<xref ref-type="bibr" rid="B150">150</xref>). In a particular disease condition, specific inhibition of either a source of ROS or an ROS toxifier may become an effective and safe intervention. Recently, proof of principle has also been shown for a surprising third alternative, that is, the functional repair of oxidatively damaged proteins (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology).</p>
<p>These three approaches hold great therapeutic promise for chronic therapy as long as they are optimally targeted, dosed, and leave physiological ROS formation intact. All are currently in clinical development with the aim to (i) prevent exacerbated ROS production by enzyme inhibition (NOX and XO); (ii) prevent the toxification of ROS such as H<sub>2</sub>O<sub>2</sub> to secondary reactive products (<italic>e.g.</italic>, by MPO); and (iii) promote functional repair of proteins that were damaged by ROS. However, these three approaches require thorough knowledge about the target proteins in addition to possible pharmacological inhibition (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology). In this review, we focus on these target enzymes and the possible future clinical indications for drugs targeting them.</p>
</sec>
</sec>
<sec id="s004">
<title>Disease-Relevant Enzymatic Sources of ROS</title>
<sec id="s005">
<title>NADPH oxidases</title>
<p>NOXs are multiprotein complexes, which contain six or seven transmembrane-spanning domains (<xref ref-type="bibr" rid="B72">72</xref>). The NOX enzyme family contains seven members, NOX1-5 and dual oxidase (DUOX)1-2 (also termed NOX6-7). Each isoform has a particular pattern of activity regulation, tissue expression, type of ROS produced, and function (<xref ref-type="table" rid="T2">Table 2</xref>) (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B81">81</xref>). The catalytic core of all NOXs contains one multimodular NADPH binding site at the C-terminus and a bimodular flavin adenine dinucleotide (FAD) binding site, as well as four conserved histidine residues involved in the binding of two heme moieties in the membrane. NOXs use NADPH as an electron donor and proximal or extracellular oxygen as an electron acceptor (<xref ref-type="bibr" rid="B27">27</xref>). Most NOX family members have similar redox centers (<xref ref-type="bibr" rid="B68">68</xref>) as well as the mechanism to generate O<sub>2</sub><sup>−</sup> as the main product. However, NOX4 and DUOX produce H<sub>2</sub>O<sub>2</sub> as their primary product (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B126">126</xref>). Other membrane, cytosolic, and regulating domains are involved in NOX activity. While NOX1-3 needs docking of cytosolic factors for complete activation, NOX4 seems to produce ROS constitutively. Yet, NOX5 and DUOX are activated by elevated cellular Ca<sup>2+</sup> concentrations <italic>via</italic> N-terminal EF-hand domains (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label><sc>Table</sc> 2.</label>
<caption>
<p>
<sc>NOXs: Isoforms and Tissue Expression</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Isoforms</italic>
</th>
<th align="center">
<italic>Tissue/cell expression</italic>
</th>
<th align="center">
<italic>Loss of function</italic>
</th>
<th align="center">
<italic>Primary ROS formed</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">NOX1</td>
<td align="left">Colon, aorta</td>
<td align="left">Not reported (mouse KO has no obvious phenotype)</td>
<td align="left">O<sub>2</sub><sup>−</sup></td>
</tr>
<tr>
<td align="left">NOX2</td>
<td align="left">Phagocytes, endothelium</td>
<td align="left">Susceptibility to infection (mouse, human), inflammation (mouse, rat, human)</td>
<td align="left">O<sub>2</sub><sup>−</sup></td>
</tr>
<tr>
<td align="left">NOX3</td>
<td align="left">Inner ear</td>
<td align="left">Absence of otoconia (mouse, rat)</td>
<td align="left">O<sub>2</sub><sup>−</sup></td>
</tr>
<tr>
<td align="left">NOX4</td>
<td align="left">Kidney, almost all tissues</td>
<td align="left">Not reported (mouse KO has no obvious phenotype)</td>
<td align="left">H<sub>2</sub>O<sub>2</sub> O<sub>2</sub><sup>−</sup></td>
</tr>
<tr>
<td align="left">NOX5</td>
<td align="left">Spleen, testis, endothelium</td>
<td align="left">Not reported (absent in rodents)</td>
<td align="left">O<sub>2</sub><sup>−</sup></td>
</tr>
<tr>
<td align="left">DUOX1/NOX6</td>
<td align="left">Thyroid, gland, lung, epithelia</td>
<td align="left">Not reported (mouse KO has no phenotype)</td>
<td align="left">H<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left">DUOX2/NOX7</td>
<td align="left">Thyroid, gland, lung, epithelia</td>
<td align="left">Hypothyroidism H<sub>2</sub>O<sub>2</sub> (mouse, human)</td>
<td align="left"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf3">
<p>DUOX, dual oxidase; O<sub>2</sub><sup>−</sup>, superoxide anion radical; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; KO, knockout; NOX, nicotinamide adenine dinucleotide phosphate oxidase; ROS, reactive oxygen species.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Because NOX is the only known enzyme family with the sole function to produce ROS (unlike XO, uc-eNOS, and mitochondria), it may represent the primary disease mechanism and thus targets for mechanism-based prevention of oxidative damage (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B110">110</xref>). Moreover, some NOX isoforms are critically regulated by Ser/Thr kinases (<italic>e.g.</italic>, PKC) (<xref ref-type="bibr" rid="B15">15</xref>), although PKC itself is upregulated by ROS (<xref ref-type="bibr" rid="B74">74</xref>). Of the seven isoforms, three are best studied: NOX1, NOX2, and NOX4. NOX3 appears to have a very limited organ-specific role both in physiology and pathophysiology. It is mostly expressed in the vestibular system of the inner ear where it controls the formation of otoconia, small biomineral particles (<xref ref-type="bibr" rid="B103">103</xref>). Mutations affecting NOX3 activity have not been described so far in humans, but its loss of function leads to severe imbalance in the head tilt mouse (<xref ref-type="bibr" rid="B69">69</xref>). NOX5 is not expressed in mice and rats and is thus understudied and remains the big unknown when it comes to translating animal data toward human pathology.</p>
<p>An involvement of NOX2 has been suggested in many disease states (<xref ref-type="bibr" rid="B76">76</xref>). The complete loss of function of NOX2 results in chronic granulomatous disease (CGD), which is characterized by susceptibility to certain fungal and bacterial infections (<xref ref-type="bibr" rid="B120">120</xref>). Foremost, CGD carriers are prone to developing autoimmune diseases, such as polyarthritis and lupus erythematosus (<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B120">120</xref>). Whether it may therefore become a safety risk for pharmacological inhibition of NOX2 and thereby compromise the innate immune response remains to be tested.</p>
<p>With respect to NOX1, it seems to be implicated in systemic hypertension (<xref ref-type="bibr" rid="B148">148</xref>). NOX1-deficient mice show a decreased angiotensin II-induced hypertensive response (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B87">87</xref>). One study also found a significant effect of NOX1 deletion on basal blood pressure (<xref ref-type="bibr" rid="B43">43</xref>). Similarly, NOX1 overexpression potentiates angiotensin II-induced hypertension (<xref ref-type="bibr" rid="B31">31</xref>). NOX1-deficient mice were also protected from angiotensin II-induced aortic aneurysms (<xref ref-type="bibr" rid="B43">43</xref>) and diabetic vasculopathies (<xref ref-type="fig" rid="f2">Fig. 2</xref>), both in the retina (<xref ref-type="bibr" rid="B147">147</xref>) and in large vessel atherosclerosis (<xref ref-type="bibr" rid="B48">48</xref>). Taken together, NOX1 may be involved in a whole range of vascular diseases and remodeling of the vascular wall.</p>
<fig fig-type="figure" id="f2" orientation="portrait" position="float">
<label>
<bold>FIG. 2.</bold>
</label>
<caption>
<p><bold>Therapeutic indications for NOX inhibitors and potential unwanted side effects.</bold> Highly validated physiological and pathological roles of different NOX isoforms based on gene knockout experiments are based on original data in stroke (<xref ref-type="bibr" rid="B73">73</xref>), diabetic atherosclerosis (<xref ref-type="bibr" rid="B48">48</xref>), diabetic nephropathy (<xref ref-type="bibr" rid="B60">60</xref>), diabetic retinopathy (<xref ref-type="bibr" rid="B147">147</xref>), and osteoporosis (<xref ref-type="bibr" rid="B157">46a</xref>). For details, see text. Based on this, NOXi seem well suited in treating acute ischemic stroke and diabetic complications.</p>
</caption>
<graphic xlink:href="fig-2"></graphic>
</fig>
<p>NOX4 is the most widely distributed isoform and can also contribute to diabetic end-organ damage, especially in the kidney (<xref ref-type="bibr" rid="B60">60</xref>). NOX4 is also upregulated under hypoxic conditions (<xref ref-type="bibr" rid="B94">94</xref>) and can function as an oxygen sensor (<xref ref-type="bibr" rid="B99">99</xref>). Pathologically, stroke is one of the best-validated disease indications for NOX4 inhibition (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B109">109</xref>) (<xref ref-type="fig" rid="f2">Fig. 2</xref>). Moreover, NOX4 expression and activity are strongly increased following TGF-β stimulation of human fibroblasts. This can lead to the transformation of not only normal fibroblasts into myofibroblasts, a key feature of wound healing, but also of chronic fibrotic diseases of the lungs, kidney, or liver. The fact that NOX4 inhibition mitigates myofibroblast transformation <italic>in vitro</italic> was first shown in cardiac and lung fibroblasts (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B53">53</xref>) and later in the bleomycin model of pulmonary fibrosis using NOX4-deficient mice (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B52">52</xref>). Interestingly, the benefit of NOX4 inhibition appears to be tissue specific as NOX4 deletion does not confer protection in urinary obstruction-induced kidney fibrosis (<xref ref-type="bibr" rid="B8">8</xref>), a condition where NOX4 inhibition even seems to be deleterious (<xref ref-type="bibr" rid="B100">100</xref>). Although the direct connection of NOX4-derived ROS and the tissue-specific fibroblast phenotypic changes are unclear, NOX4 inhibition in idiopathic lung fibrosis represents another promising indication for a pharmacological intervention targeting NOX4.</p>
<p>Finally, the NOX5 isoform, which is not expressed in mice or rats (<xref ref-type="bibr" rid="B11">11</xref>), is unique as it is directly activated by calcium (<xref ref-type="bibr" rid="B10">10</xref>) and may thus directly link cellular calcium overload to oxidative stress. In adults, NOX5 is found mostly in the spleen, lymph node, and the reproductive and vascular systems (<xref ref-type="bibr" rid="B39">39</xref>); in disease, it may play a role in coronary artery disease (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>DUOX enzymes are expressed at high levels in the thyroid glands and generate H<sub>2</sub>O<sub>2</sub> at the apical membrane. Mutations in DUOX2 and DUOXA2 lead to defects in thyroidal H<sub>2</sub>O<sub>2</sub> generation, congenital hypothyroidism, and euthyroid goiter (<xref ref-type="bibr" rid="B61">61</xref>).</p>
<p>Despite the rich genetic evidence for distinct roles of different NOX isoforms (<xref ref-type="bibr" rid="B3">3</xref>), the development of isoform-specific inhibitors is lagging behind (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology). The first generation of inhibitors was highly unspecific, that is, not even specific for NOX (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B149">149</xref>), while, more recently, the achieved differences in IC<sub>50</sub> of the second-generation NOX-specific compounds are hardly relevant <italic>in vivo</italic> (<xref ref-type="bibr" rid="B4">4</xref>). However, with the increasing interest in this target both in pharmaceutical and biotech industries, a third generation of inhibitors, specific and isoform selective, is on the horizon (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology).</p>
</sec>
<sec id="s006">
<title>NOS</title>
<p>In this review, we consider nitric oxide (NO) a member of the ROS family. NO is generated from <sc>l</sc>-arginine, contains an unpaired electron (making it a free radical), and reacts with O<sub>2</sub><sup>−•</sup> in a diffusion-limited manner to form the highly reactive peroxynitrite. Three NOS isoforms exist: NOS1 is predominantly present in the central and peripheral nervous system (thus it is also named nNOS); NOS2, in macrophages; and NOS3 in eNOS (<xref ref-type="bibr" rid="B123">123</xref>). Importantly, NOS3 has also to be considered as a target of ROS, leading to reversible uncoupling (see chapter below on proteins reversibly damaged by ROS).</p>
<p>Mice with genetic deficiencies in one of the NOS isoforms are viable. Nos1<sup>−/−</sup> mice show impaired cognitive performance (<xref ref-type="bibr" rid="B145">145</xref>), dramatic enlargement of the stomach, and significantly reduced brain damage after cerebral ischemia (<xref ref-type="bibr" rid="B84">84</xref>). Nos2<sup>−/−</sup> mice suffer from impaired host defense against pathogens and are prone to severe infections. However, they are protected from life-threatening hypotension in septic shock (<xref ref-type="bibr" rid="B84">84</xref>). Nos3<sup>−/−</sup> mice display impaired vasodilation, elevated blood pressure, diminished cardiac contractility (<xref ref-type="bibr" rid="B84">84</xref>), and, under stress conditions, impaired adaptation, for example, increased atherogenesis under high-fat diet and accelerated development of diabetic complications (<xref ref-type="bibr" rid="B18">18</xref>). Double knockout mice that lack both NOS1 and NOS3 display abnormalities in hippocampal long-term potentiation, a model for learning and memory (<xref ref-type="bibr" rid="B7">7</xref>). Triple knockout mice are severely insulin resistant (nephrogenic diabetes insipidus), display a number of cardiovascular risk factors, including hypertension and hypertriglyceridemia, and develop spontaneous myocardial infarction, supporting a critical role of NO in maintaining cardiovascular homeostasis (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B138">138</xref>). Clinically, many reports suggested therapeutic benefit from inhibiting NOS1 or NOS2, for example, asthma (<xref ref-type="bibr" rid="B51">51</xref>), migraine (<xref ref-type="bibr" rid="B139">139</xref>), or cardiovascular diseases (CVDs) (<xref ref-type="bibr" rid="B2">2</xref>). Currently, the clinically most advanced therapeutic approach for NOS inhibition is in traumatic brain injury (<xref ref-type="bibr" rid="B133">133</xref>) (<xref ref-type="fig" rid="f3">Fig. 3</xref>).</p>
<fig fig-type="figure" id="f3" orientation="portrait" position="float">
<label>
<bold>FIG. 3.</bold>
</label>
<caption>
<p><bold>VAS203 treatment against brain traumatic injury. (A)</bold> NADPH donates electrons to the reductase domain of NOS. They are transferred <italic>via</italic> FAD and FMN to the oxygenase domain where they reduce heme-bound oxygen and an intermediate role of BH4. Activated oxygen oxidizes a guanidine nitrogen of <sc>l</sc>-arginine to produce NO and <sc>l</sc>-citrulline (<xref ref-type="bibr" rid="B155">1a</xref>). VAS203 is an analog of the physiological NOS cofactor tetrahydrobiopterin, which enables blockade of NOS activity. VAS203 exhibits more suitable properties than other classical arginine NOS inhibitors (<italic>i.e.</italic>, L-N<sup>6</sup>-Nitroarginine methyl ester [L-NAME]). <bold>(B)</bold> VAS203-treated patients significantly reduced the therapeutic intensity level after a 6-day observation period. <bold>(C)</bold> The median level in the extended Glasgow Outcome Score after 6 months was 1.5 score points higher under VAS203 treatment compared with placebo (<xref ref-type="bibr" rid="B133">133</xref>). NOS, nitric oxide synthase. *Statistically significant difference between VAS203 (30 mg/kg) treatment and TL-placebo</p>
</caption>
<graphic xlink:href="fig-3"></graphic>
</fig>
</sec>
<sec id="s007">
<title>XO</title>
<p>XO is defined as an enzyme activity; it utilizes oxygen as the electron acceptor to form reduced ROS (<xref ref-type="bibr" rid="B89">89</xref>) according to the following:
<disp-formula><tex-math id="eq1" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}{ \rm Xanthine} + { \rm H}_2{ \rm O} + { \rm O}_2
\rightarrow { \rm Uric \ acid} + { \rm H}_2{ \rm O}2\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq2" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*} \\ { \rm Xanthine} + { \rm H}_2{ \rm O} + 2 { \rm
O}_2 \rightarrow { \rm Uric \ acid} + 2 { \rm O}_2^{ -} + 2 { \rm
H}^ +\end{align*}
\end{document}</tex-math></disp-formula></p>
<p>XO is derived from xanthine dehydrogenase (XDH, encoded by <italic>Xdh</italic>) by reversible sulfhydryl oxidation or by irreversible proteolytic modification (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B98">98</xref>). As the terminal enzyme in the catabolism of purines, XDH activity utilizes NAD<sup>+</sup> as the electron acceptor to convert hypoxanthine to xanthine and the latter to uric acid, according to the following:
<disp-formula><tex-math id="eq3" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}{ \rm Hypoxanthine} + { \rm NAD}^{ +} + { \rm H}_2{
\rm O} \rightarrow { \rm Xanthine} + { \rm NADH} + { \rm
H}\end{align*}
\end{document}</tex-math></disp-formula>
<disp-formula><tex-math id="eq4" notation="LaTeX">\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*} \\ { \rm Xanthine} + { \rm NAD} + { \rm H}_2{ \rm
O} \rightarrow { \rm Uric \ acid} + { \rm NADH} + { \rm H}^
+\end{align*}
\end{document}</tex-math></disp-formula></p>
<p>In some mammals, such as mice, uric acid is metabolized further by uricase to form allantoin. As XO may arise from XDH by sulfhydryl oxidation, XO activity can be a direct consequence of increased oxidative stress that further contributes to the pathogenesis of various diseases as a feed-forward mechanism of ROS-induced ROS.</p>
<p>Homozygous <italic>Xdh</italic><sup>−/−</sup> mice show early neonatal lethality and display renal dysplasia (<xref ref-type="bibr" rid="B106">106</xref>), while heterozygous <italic>Xdh<sup>+</sup></italic><sup>/−</sup> mice have disrupted formation of the milk fat globule, underlining the importance of XDH to lactation (<xref ref-type="bibr" rid="B38">38</xref>). Reduced expression of <italic>Xdh</italic> in mice augments lipid accumulation in adipocytes, accompanied by an increase in oxidative stress, and induces obesity with insulin resistance in older age groups (<xref ref-type="bibr" rid="B96">96</xref>).</p>
<p>Inhibition of XO has been clinically applied for decades for the treatment of hyperuricemia and gout (<xref ref-type="bibr" rid="B35">35</xref>). In addition, xanthine oxidase inhibitors (XOi) has recently been explored for cardiovascular therapy (<xref ref-type="fig" rid="f4">Fig. 4</xref>) based on animal (<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B135">135</xref>) and clinical studies in patients with type 2 diabetes and idiopathic dilated cardiomyopathy (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). While several studies show clinical efficacy of XOi in CVD, others do not, such as in the case of heart failure patients with hyperuricemia (<xref ref-type="bibr" rid="B46">46</xref>). A possible explanation for these contradicting results is that XO inhibition might be a double-edged sword. Thus, while XO generates O<sub>2</sub><sup>−</sup>/H<sub>2</sub>O<sub>2</sub> as by-products, its final metabolite, uric acid, is also an antioxidant. Depending on the disease condition, one of these opposite effects of XO (ROS or antioxidant production) may prevail. This notion is consistent with the observation that plasma uric acid concentrations associate inversely with some diseases (<xref ref-type="bibr" rid="B144">144</xref>), whereas they are independently and significantly associated with other diseases (<xref ref-type="bibr" rid="B37">37</xref>).</p>
<fig fig-type="figure" id="f4" orientation="portrait" position="float">
<label>
<bold>FIG. 4.</bold>
</label>
<caption>
<p><bold>Role of XO in ischemia–reperfusion-induced oxidative stress.</bold> During ischemia, ATP causes accumulation of its catabolite, hypoxanthine. Ischemia also induces conversion of XD into XO. During reperfusion, with oxygen available again, hypoxanthine is oxidized to uric acid, while molecular oxygen is concomitantly reduced to O<sub>2</sub><sup>−</sup>. Scheme derived from (<xref ref-type="bibr" rid="B89">89</xref>).</p>
</caption>
<graphic xlink:href="fig-4"></graphic>
</fig>
</sec>
<sec id="s008">
<title>MAO</title>
<p>MAOs are flavoenzymes (located at the outer mitochondrial membrane) that catalyze the oxidative deamination of both endogenous and exogenous amines, including neurotransmitters and several drugs. They exist as two isoforms, A and B, differing with respect to their tissue distribution, substrate preference, and inhibitor specificity (<xref ref-type="bibr" rid="B111">111</xref>). MAO-A reacts preferentially with tyramine, serotonin, and norepinephrine, while dopamine and phenylethylamine are preferential substrates for MAO-B. The imine products are coupled to the reduction of a covalently bound FAD, which in turn is reoxidized by oxygen leading to H<sub>2</sub>O<sub>2</sub>. In mitochondria, MAOs thus generate a significant percentage of total H<sub>2</sub>O<sub>2</sub> in addition to that formed by the electron transport chain (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B64">64</xref>). On the other hand, the imine product can also spontaneously hydrolyze, generating the corresponding aldehyde and ammonia (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B111">111</xref>). Of note, all the three products of MAO catalysis are potentially toxic, especially at the level of mitochondria (<xref ref-type="bibr" rid="B64">64</xref>). In this regard, H<sub>2</sub>O<sub>2</sub> and aldehydes can particularly synergize (<xref ref-type="bibr" rid="B62">62</xref>) leading to mitochondrial dysfunction. Moreover, they are directly related to endothelial dysfunction, heart function, and muscular dystrophy (<xref ref-type="fig" rid="f5">Fig. 5</xref>). In addition, ammonia can stimulate further ROS formation by dihydrolipoyl dehydrogenase, the E3 component of pyruvate and oxoglutarate dehydrogenase (<xref ref-type="bibr" rid="B67">67</xref>).</p>
<fig fig-type="figure" id="f5" orientation="portrait" position="float">
<label>
<bold>FIG. 5.</bold>
</label>
<caption>
<p><bold>Schematic representation of the mechanisms underlying the contribution of MAO activity to pathological conditions.</bold> Although the scheme focuses on cardiovascular and muscular diseases, especially heart failure, endothelial dysfunction, or muscular dystrophy, similar pathological mechanisms based upon mitochondrial dysfunction are likely to act also in other organs.</p>
</caption>
<graphic xlink:href="fig-5"></graphic>
</fig>
<p>Patients and mice lacking MAO-A activity are characterized by borderline mental retardation and aggressive behavior (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>), whereas polymorphisms in the MAO-A gene have been associated with bipolar disorder (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B114">114</xref>). On the other hand, variations in MAO-B activity in patients have been associated with psychotic disorders, depression, impulsivity, behavioral disinhibition, and attention-deficit/hyperactivity disorder (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B112">112</xref>). MAO inhibitors have been used for the treatment of affective disorders and their mood-enhancing effect of MAO inhibition is likely related to an increased availability of serotonin, norepinephrine, and dopamine since their decrease is associated with depression (<xref ref-type="bibr" rid="B154">154</xref>). Deficit in both MAO-A and -B activity causes severe developmental and intellectual deficits, autistic-like behavior, and stereotypical movements (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>, <xref ref-type="bibr" rid="B146">146</xref>).</p>
<p>The emphasis on MAO substrates (<italic>i.e.</italic>, neurotransmitters) has curtailed the attention on the relevance of MAO products. Increased MAO-B activity has been correlated with Parkinson's disease (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B117">117</xref>). MAO expression increases in aging (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B118">118</xref>) and an increased expression is associated with endothelial dysfunction (<xref ref-type="bibr" rid="B134">134</xref>), postoperative atrial fibrillation, muscular dystrophy (<xref ref-type="bibr" rid="B91">91</xref>), and prostate cancer (<xref ref-type="bibr" rid="B152">152</xref>). A common denominator among all these pathologies is altered ROS. In agreement with this, beneficial effects of MAO inhibition have been demonstrated in these conditions as well as in myocardial ischemia/reperfusion injury (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B30">30</xref>), heart failure (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B140">140</xref>), and neurodegenerative disorders (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
</sec>
<sec id="s009">
<title>ROS Toxifiers</title>
<p>ROS toxifiers include different peroxidases such us eosinophil peroxidase, lactoperoxidase, and thyroid peroxidase. These enzymes share several similarities with their ortholog, MPO. However, here we mainly focus on MPO due to its clinical relevance and promising preclinical data.</p>
<sec id="s010">
<title>MPO</title>
<p>MPO, a heme peroxidase present in circulating neutrophils, monocytes, and some tissue macrophages, plays an important role in killing invading microbes (<xref ref-type="bibr" rid="B71">71</xref>). MPO generates a number of reactive chlorinating and brominating oxidants, including nonradical species (two-electron oxidants) and radical species (<xref ref-type="bibr" rid="B50">50</xref>). In fact, MPO acts as a toxifier since in the presence of halides (Cl<sup>−</sup>, Br<sup>−</sup>), it transforms the relatively weak two-electron oxidant H<sub>2</sub>O<sub>2</sub> into the more reactive hypohalous acids, (hypochlorous acid, [HOCl]; and hypobromous acid, [HOBr]) (<xref ref-type="bibr" rid="B150">150</xref>), as well as chloramines (<xref ref-type="bibr" rid="B104">104</xref>). MPO is also a major contributor to protein nitration since inflamed tissues of MPO-deficient mice contain significantly less 3-nitrotyrosine than those in wild-type mice (<xref ref-type="bibr" rid="B41">41</xref>). In addition to their role in the innate immune response, MPO-derived oxidants have the potential to cause host tissue injury by promoting post-translational protein modification (<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B150">150</xref>) and lipid oxidation (<xref ref-type="bibr" rid="B119">119</xref>). MPO was demonstrated to promote CVD and pharmacological inhibition or genetic deletion partially prevented these adverse effects (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B141">141</xref>). However, it should be noted that MPO also fulfills an important role in host defense against pathogens and genetic deletion increased the severity of infections in animal models, although no clear increase in susceptibility to infections was observed in humans with MPO polymorphisms (<xref ref-type="bibr" rid="B34">34</xref>). Therefore, although MPO is detrimental in the context of CVDs, it also plays a major role in defense against pathogens, thus partial inhibition may be better than a complete blockage of the enzyme (see related review by Dao <italic>et al.</italic> in this Forum on the New ROS Pharmacology).</p>
<p>MPO is predominately located in inflamed tissue where it is found within or nearby infiltrated neutrophils and certain macrophages. Upon activation, phagocytes release MPO. In the case of circulating neutrophils, released MPO can bind to the endothelium, translocate, and be deposited in the subendothelial space (<xref ref-type="bibr" rid="B101">101</xref>). As a consequence of its localization and production of highly reactive oxidants, MPO is thought to contribute to a wide range of chronic inflammatory diseases as well as cardiovascular and neuroinflammatory diseases.</p>
<p>In addition to inhibiting MPO activity directly, an alternative therapeutic strategy is to displace MPO from the vascular endothelium and subendothelial space, that is, the sites where MPO released from circulating phagocytes is thought to bind to and reside. MPO binds to endothelial cells <italic>via</italic> heparin sulfate glycosaminoglycan, and heparin prevents and reverses such binding (<xref ref-type="bibr" rid="B9">9</xref>). The removal of MPO by heparin may help explain its anti-inflammatory actions. In fact, infusion of heparin increases the plasma concentration of MPO and increases flow-mediated dilatation (<xref ref-type="bibr" rid="B115">115</xref>), a major indicator of endothelial nitric oxide bioavailability.</p>
<p>Targeting MPO is in the early stages of clinical development, for example, as treatment for neurodegenerative, cardiovascular, and pulmonary diseases. Therefore, the next few years will be crucial in providing a definitive answer on whether inhibition of this toxifier enzyme is a valid strategy for preventing or alleviating various inflammatory diseases.</p>
</sec>
</sec>
<sec id="s011">
<title>Proteins Damaged by ROS</title>
<p>In addition to preventing ROS-induced damage, its functional repair is much more than an option and has already entered clinical practice. A key example of this is impaired NO-cyclic guanosine monophosphate (cGMP) signaling.</p>
<sec id="s012">
<title>uc-eNOS, NO scavenging, and apo-sGC</title>
<p>NO is an important cellular signaling molecule, which is involved in many physiological processes (<xref ref-type="bibr" rid="B58">58</xref>). NO production and ROS activate PKC, which contributes to cellular proliferation, neoplasia, and cancer (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B113">113</xref>). Besides, NO interacts with different receptors (<italic>i.e.</italic>, NMDAR and G-protein-coupled receptors) promoting the release of zinc ions from metallothioneins mediated by the nNOS/NO pathway (<xref ref-type="bibr" rid="B116">116</xref>). Accumulation of zinc is related to mood disorders, schizophrenia, and both neurological and neurodegenerative diseases (<xref ref-type="bibr" rid="B108">108</xref>).</p>
<p>However, almost all physiological effects of NO are mediated through its receptor enzyme, sGC, a heterodimeric heme protein comprising of a larger α subunit and a smaller heme-binding β subunit. Upon binding of NO to sGC heme, the conversion of guanosine-5′-triphosphate to the intracellular signaling molecule, cGMP, is activated. cGMP in turn regulates cGMP-dependent protein kinases and ion channels and is degraded by phosphodiesterases (<xref ref-type="bibr" rid="B29">29</xref>). The resulting effects include (acutely) inhibition of blood vessel contraction, improved perfusion, antithrombosis, neurotransmission, and memory formation, as well as (chronically) antiproliferation, antiremodeling, and anti-inflammation effects (<xref ref-type="bibr" rid="B123">123</xref>).</p>
<p>Oxidative stress can lead to the deregulation of NO-cGMP signaling (<xref ref-type="bibr" rid="B90">90</xref>) either by oxidizing and uncoupling NOS, by chemical scavenging of NO, or by oxidation and loss of heme in sGC. NOS3/eNOS, NOS1/nNOS (<xref ref-type="bibr" rid="B93">93</xref>), and to a lesser extent NOS2/iNOS (<xref ref-type="bibr" rid="B153">153</xref>) can be oxidatively damaged. This involves a highly redox-sensitive cofactor, tetrahydrobiopterin (H<sub>4</sub>B). In uc-NOS, oxygen activation is uncoupled from arginine-to-NO metabolism and NOSs become themselves ROS-forming enzymes; another example of ROS-induced ROS formation.</p>
<p>Impaired NO-sGC-cGMP signaling can thus be caused by reduced NO bioavailability and/or decreased responsiveness to NO and has been implicated in the pathogenesis of many cardiovascular, pulmonary, endothelial, renal, and neurological diseases (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B148">148</xref>). Clinical evidence for a role of oxidative H<sub>4</sub>B depletion is based on recoupling and improvement of endothelial function in chronic smokers by BH4, but not by tetrahydroneopterin (H<sub>4</sub>N), which shares the antioxidant properties of H<sub>4</sub>B, but is not a cofactor for NOS3/eNOS (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Likewise, supplementation with the BH4 analog, folic acid, improves endothelial function in human subjects (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B47">47</xref>). In fact, in experimental hypertension as well as atherosclerosis treatment with the H<sub>4</sub>B precursor, sepiapterin restores endothelial function (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B125">125</xref>). In addition, many studies have reported a positive effect of <sc>l</sc>-arginine supplementation in endothelial dysfunction (<xref ref-type="bibr" rid="B136">136</xref>). This is surprising as arginine plasma levels by far exceed the <italic>K<sub>m</sub></italic> of eNOS for <sc>l</sc>-arginine. A possible explanation for the protective effects of high-dose <sc>l</sc>-arginine administration may reside in the competition of <sc>l</sc>-arginine with an endogenous competitive inhibitor at the <sc>l</sc>-arginine binding site, asymmetric dimethyl <sc>l</sc>-arginine (ADMA), or the normalization of intracellular ADMA levels (<xref ref-type="bibr" rid="B24">24</xref>). Because of lower bioavailability of <sc>l</sc>-arginine in humans <italic>versus</italic> rodents, <sc>l</sc>-citrulline may be a better alternative and is subject to ongoing trials (Australian New Zealand Clinical Trials Registry ACTRN12609000882224).</p>
<p>In addition to NOS, ROS can also affect the bioavailability of NO by direct chemical scavenging and the redox state of sGC resulting in the oxidation of its heme iron to Fe<sup>3+</sup> and/or ultimately in loss of the sGC heme (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B131">131</xref>). The resulting apo-sGC is completely unresponsive to NO and rapidly degrades (<xref ref-type="bibr" rid="B92">92</xref>). Both pathomechanisms can be functionally reversed. So-called sGC stimulators sensitize sGC for lower NO concentrations to yield the same cGMP stimulatory effects as physiological NO levels would cause; sGC activators bind to the oxidized/heme-free form of sGC and reactivate the enzyme to the same V<sub>max</sub> levels as NO-stimulated heme-containing sGC.</p>
<p>sGC stimulators have entered the clinic. The PATENT-1 and PATENT-2 clinical trials in pulmonary arterial hypertension patients showed an increased walking distance (<xref ref-type="bibr" rid="B45">45</xref>). Moreover, the CHEST-1 trial in chronic thromboembolic pulmonary hypertension, for which otherwise pulmonary endarterectomy has been the only other curative option, showed improved exercise capacity, mean pulmonary artery pressure, cardiac output, and decreased clinically relevant pulmonary vascular resistance. A second sGC stimulator, vericiguat, is now in clinical development for different forms of heart failure (<xref ref-type="bibr" rid="B105">105</xref>). In addition, preclinical data suggest that sGC stimulators may be of benefit in chronic kidney disease (<xref ref-type="bibr" rid="B130">130</xref>) and hypertension (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B143">143</xref>).</p>
<p>The development of sGC activators lags behind that of sGC stimulators due to initial pharmacokinetic setbacks (<xref ref-type="bibr" rid="B44">44</xref>), but preclinical data suggest benefit in cardiac hypertrophy (<xref ref-type="bibr" rid="B26">26</xref>) and type 2 diabetic nephropathy (<xref ref-type="bibr" rid="B102">102</xref>). Importantly, these effects seem to occur at doses that do not affect mean arterial pressure and heart rate and may thus involve preferential microvascular dilation.</p>
</sec>
</sec>
<sec id="s013" sec-type="conclusions">
<title>Conclusions</title>
<p>For several decades redox imbalances have been suggested to have relevance in neurodegenerative, cardiovascular, metabolic, and neoplastic diseases. Therapeutically, most attempts to translate ROS scavenging by antioxidants into the clinic have yielded mostly disappointing results. However, pharmacological modulation of protein targets to either decrease ROS overproduction or toxification, as well as functional reversal of ROS-induced damage, has lead to several therapeutic breakthroughs (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label><sc>Table</sc> 3.</label>
<caption>
<p>
<sc>Pathological Role of Enzymatic Reactive Oxygen Species Sources and Their Current Clinical Status</sc>
</p>
</caption>
<!--OASIS TABLE HERE-->
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">
<italic>Target</italic>
</th>
<th align="center">
<italic>Pathology</italic>
</th>
<th align="center">
<italic>Current status of clinical translation</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">NOX</td>
<td align="left">Type 2 diabetes mellitus associated with diabetic nephropathy (<xref ref-type="bibr" rid="B68">68</xref>)</td>
<td align="left">Reduction in both liver enzyme and inflammatory marker levels, primary efficacy endpoints, albuminuria, not achieved (NCT 02010242)</td>
</tr>
<tr>
<td align="left">NOS</td>
<td align="left">Septic shock (<xref ref-type="bibr" rid="B91">91</xref>)</td>
<td align="left">Failure in treatment against septic shock (<xref ref-type="bibr" rid="B91">91</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Asthma (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left">No improvement of respiratory functions (<xref ref-type="bibr" rid="B58">58</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Acute migraine (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B145">145</xref>)</td>
<td align="left">Ineffective in the treatment of acute migraine (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B145">145</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Cardiogenic shock complicating acute myocardial infarction (<xref ref-type="bibr" rid="B2">2</xref>)</td>
<td align="left">Did not reduce mortality in patients with refractory cardiogenic shock (<xref ref-type="bibr" rid="B2">2</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Traumatic brain injury (<xref ref-type="bibr" rid="B139">139</xref>)</td>
<td align="left">Phase II clinical trial complete</td>
</tr>
<tr>
<td align="left">XO</td>
<td align="left">CVD (<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B141">141</xref>), type 2 diabetes (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>)</td>
<td align="left">Improves endothelial function in patients with CVD (<xref ref-type="bibr" rid="B64">64</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Gout (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td align="left">More effective than allopurinol in gout patients (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B27">27</xref>)</td>
</tr>
<tr>
<td align="left">MPO</td>
<td align="left">Multiple sclerosis and COPD (<xref ref-type="bibr" rid="B28">28</xref>)</td>
<td align="left">Phase I clinical trial for COPD and multiple sclerosis</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Parkinson's disease (<xref ref-type="bibr" rid="B115">115</xref>)</td>
<td align="left">Phase IIA clinical trial in patients with Parkinson's disease</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">CVD (<xref ref-type="bibr" rid="B89">89</xref>)</td>
<td align="left">Positive results in preclinical animal models (<xref ref-type="bibr" rid="B89">89</xref>)</td>
</tr>
<tr>
<td align="left">NOS</td>
<td align="left">CVD</td>
<td align="left">Reverses pulmonary hypertension (<xref ref-type="bibr" rid="B43">43</xref>)</td>
</tr>
<tr>
<td align="left">sGC</td>
<td align="left">PAH (<xref ref-type="bibr" rid="B18">18</xref>)</td>
<td align="left">Entered in the clinic (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B52">52</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Heart failure (<xref ref-type="bibr" rid="B112">112</xref>)</td>
<td align="left">Phase II clinical trial. Still open—recruiting</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Acute heart failure (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left">Still in clinical development. Phase IIb clinical trial complete (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B51">51</xref>)</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Acute heart failure (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left">Still in clinical development</td>
</tr>
<tr>
<td align="left">MAO</td>
<td align="left">Parkinson's disease, dementia, and depression (<xref ref-type="bibr" rid="B5">5</xref>)</td>
<td align="left">In the clinic</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left">Parkinson's disease, dementia, and depression (<xref ref-type="bibr" rid="B5">5</xref>)</td>
<td align="left">In the clinic</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf4">
<p>CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; MAO, monoamine oxidase; MPO, myeloperoxidase; NOS, nitric oxide synthase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; PAH, pulmonary arterial hypertension; sGC, soluble guanylate cyclase; XO, xanthine oxidase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s014">
<title>Outlook</title>
<p>With the introduction of sGC stimulators for pulmonary hypertension, repurposing of XOi and monoamine oxidase inhibitors for ROS-related cardiovascular indications and the successful development of several new principles such as NOXi, MPOi, and NOSi into phase III translational ROS research are at the verge of major breakthroughs. Several of these candidate compounds are currently in clinical development and are likely to dramatically reshape the perception of the field of ROS and oxidative stress.</p>
</sec>
</body>
<back>
<sec id="s015" sec-type="ack">
<title>Acknowledgments</title>
<p>A.I.C., A.D., F.D.L., V.J., T.S., K.H.K., M.G.L., A.C., P.G., and H.H.H.W.S. were supported by the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS). N.K. is supported by an EFSD/Sanofi Award. H.H.H.W.S. is the recipient of an ERC Advanced Grant and a Marie Curie IRG. R.S. is supported by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia.</p>
</sec>
<ref-list content-type="parsed">
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolfsson</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gottfries</surname><given-names>CG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oreland</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wiberg</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name></person-group>
<article-title>Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type</article-title>. <source/>Life Sci
<volume>27</volume>: <fpage>1029</fpage>–<lpage>1034</lpage>, <year>1980</year><pub-id pub-id-type="pmid">7421397</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>1a.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderton</surname><given-names>WK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CE</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Knowles</surname><given-names>RG</given-names></name></person-group>
<article-title>Nitric oxide synthases: structure, function and inhibition</article-title>. <source/>Biochem J
<volume>357</volume>: <fpage>593</fpage>–<lpage>615</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11463332</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>JH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>HR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stebbins</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dzavik</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harrington</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Van de Werf</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hochman</surname><given-names>JS</given-names></name></person-group>
<article-title>Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial</article-title>. <source/>JAMA
<volume>297</volume>: <fpage>1657</fpage>–<lpage>1666</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17387132</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altenhofer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleikers</surname><given-names>PW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Radermacher</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scheurer</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rob Hermans</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schiffers</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ho</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>The NOX toolbox: validating the role of NADPH oxidases in physiology and disease</article-title>. <source/>Cell Mol Life Sci
<volume>69</volume>: <fpage>2327</fpage>–<lpage>2343</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22648375</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altenhofer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Radermacher</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleikers</surname><given-names>PW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement</article-title>. <source/>Antioxid Redox Signal
<volume>23</volume>: <fpage>406</fpage>–<lpage>427</lpage>, <year>2015</year><pub-id pub-id-type="pmid">24383718</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>EJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Efird</surname><given-names>JT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Neal</surname><given-names>WT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Darden</surname><given-names>TM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thayne</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Katunga</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kindell</surname><given-names>LC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>TB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anderson</surname><given-names>CA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chitwood</surname><given-names>WR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Koutlas</surname><given-names>TC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Williams</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Kypson</surname><given-names>AP</given-names></name></person-group>
<article-title>Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation</article-title>. <source/>J Am Heart Assoc
<volume>3</volume>: <fpage>e000713</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24572256</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniades</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shirodaria</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Warrick</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cai</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de Bono</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leeson</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neubauer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ratnatunga</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pillai</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Refsum</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Channon</surname><given-names>KM</given-names></name></person-group>
<article-title>5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling</article-title>. <source/>Circulation
<volume>114</volume>: <fpage>1193</fpage>–<lpage>1201</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16940192</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atochin</surname><given-names>DN</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Huang</surname><given-names>PL</given-names></name></person-group>
<article-title>Endothelial nitric oxide synthase transgenic models of endothelial dysfunction</article-title>. <source/>Pflugers Arch
<volume>460</volume>: <fpage>965</fpage>–<lpage>974</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20697735</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babelova</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Avaniadi</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jung</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fork</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beckmann</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kosowski</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anilkumar</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shah</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group>
<article-title>Role of Nox4 in murine models of kidney disease</article-title>. <source/>Free Radic Biol Med
<volume>53</volume>: <fpage>842</fpage>–<lpage>853</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22749956</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldus</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eiserich</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mani</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Castro</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chumley</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tousson</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>White</surname><given-names>CR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bullard</surname><given-names>DC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brennan</surname><given-names>M-L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moore</surname><given-names>KP</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group>
<article-title>Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration</article-title>. <source/>J Clin Invest
<volume>108</volume>: <fpage>1759</fpage>–<lpage>1770</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11748259</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banfi</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Molnar</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maturana</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Steger</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hegedus</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Demaurex</surname><given-names>N</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes</article-title>. <source/>J Biol Chem
<volume>276</volume>: <fpage>37594</fpage>–<lpage>37601</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11483596</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedard</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jaquet</surname><given-names>V</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>NOX5: from basic biology to signaling and disease</article-title>. <source/>Free Radic Biol Med
<volume>52</volume>: <fpage>725</fpage>–<lpage>734</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22182486</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedard</surname><given-names>K</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology</article-title>. <source/>Physiol Rev
<volume>87</volume>: <fpage>245</fpage>–<lpage>313</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17237347</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bialecka</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klodowska-Duda</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Honczarenko</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gawronska-Szklarz</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Opala</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Safranow</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Drozdzik</surname><given-names>M</given-names></name></person-group>
<article-title>Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease</article-title>. <source/>Parkinsonism Relat Disord
<volume>13</volume>: <fpage>224</fpage>–<lpage>229</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17270484</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kunduzova</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Masini</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cambon</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bani</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Raimondi</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Seguelas</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nistri</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Colucci</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leducq</surname><given-names>N</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Parini</surname><given-names>A</given-names></name></person-group>
<article-title>Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury</article-title>. <source/>Circulation
<volume>112</volume>: <fpage>3297</fpage>–<lpage>3305</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16286591</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokoch</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Diebold</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Gianni</surname><given-names>D</given-names></name></person-group>
<article-title>Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases</article-title>. <source/>Antioxid Redox Signal
<volume>11</volume>: <fpage>2429</fpage>–<lpage>2441</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19358632</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolato</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>
<article-title>Monoamine oxidase inactivation: from pathophysiology to therapeutics</article-title>. <source/>Adv Drug Deliv Rev
<volume>60</volume>: <fpage>1527</fpage>–<lpage>1533</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18652859</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolato</surname><given-names>M</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>
<article-title>Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence</article-title>. <source/>Int Rev Neurobiol
<volume>100</volume>: <fpage>13</fpage>–<lpage>42</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21971001</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bressler</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pankow</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Coresh</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Boerwinkle</surname><given-names>E</given-names></name></person-group>
<article-title>Interaction between the NOS3 gene and obesity as a determinant of risk of type 2 diabetes: the atherosclerosis risk in communities study</article-title>. <source/>PLoS One
<volume>8</volume>: <fpage>e79466</fpage>, <year>2013</year><pub-id pub-id-type="pmid">24278136</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nelen</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Breakefield</surname><given-names>XO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ropers</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>van Oost</surname><given-names>BA</given-names></name></person-group>
<article-title>Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A</article-title>. <source/>Science
<volume>262</volume>: <fpage>578</fpage>–<lpage>580</lpage>, <year>1993</year><pub-id pub-id-type="pmid">8211186</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nelen</surname><given-names>MR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van Zandvoort</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Abeling</surname><given-names>NG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van Gennip</surname><given-names>AH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wolters</surname><given-names>EC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ropers</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>van Oost</surname><given-names>BA</given-names></name></person-group>
<article-title>X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism</article-title>. <source/>Am J Hum Genet
<volume>52</volume>: <fpage>1032</fpage>–<lpage>1039</lpage>, <year>1993</year><pub-id pub-id-type="pmid">8503438</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morris</surname><given-names>AD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belch</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hill</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Struthers</surname><given-names>AD</given-names></name></person-group>
<article-title>Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension</article-title>. <source/>Hypertension
<volume>35</volume>: <fpage>746</fpage>–<lpage>751</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10720589</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappola</surname><given-names>TP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kass</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nelson</surname><given-names>GS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Berger</surname><given-names>RD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rosas</surname><given-names>GO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kobeissi</surname><given-names>ZA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marban</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hare</surname><given-names>JM</given-names></name></person-group>
<article-title>Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy</article-title>. <source/>Circulation
<volume>104</volume>: <fpage>2407</fpage>–<lpage>2411</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11705816</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnesecchi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deffert</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Donati</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Basset</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Preynat-Seauve</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guichard</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Arbiser</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Banfi</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pache</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barazzone-Argiroffo</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>A key role for NOX4 in epithelial cell death during development of lung fibrosis</article-title>. <source/>Antioxid Redox Signal
<volume>15</volume>: <fpage>607</fpage>–<lpage>619</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21391892</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Closs</surname><given-names>EI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ostad</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Simon</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Warnholtz</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jabs</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Habermeier</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daiber</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forstermann</surname><given-names>U</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>
<article-title>Impairment of the extrusion transporter for asymmetric dimethyl-l-arginine: a novel mechanism underlying vasospastic angina</article-title>. <source/>Biochem Biophys Res Commun
<volume>423</volume>: <fpage>208</fpage>–<lpage>223</lpage>, <year>2012</year></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>FA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reiss</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sims</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Freund</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karoum</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhu</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maumenee</surname><given-names>IH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group>
<article-title>Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes</article-title>. <source/>Am J Med Genet
<volume>42</volume>: <fpage>127</fpage>–<lpage>134</lpage>, <year>1992</year><pub-id pub-id-type="pmid">1308352</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costell</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ancellin</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bernard</surname><given-names>RE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Upson</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morgan</surname><given-names>LA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maniscalco</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olzinski</surname><given-names>AR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ballard</surname><given-names>VL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herry</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grondin</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dodic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mirguet</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bouillot</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gellibert</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Coatney</surname><given-names>RW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lepore</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jucker</surname><given-names>BM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jolivette</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Willette</surname><given-names>RN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schnackenberg</surname><given-names>CG</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Behm</surname><given-names>DJ</given-names></name></person-group>
<article-title>Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress</article-title>. <source/>Front Pharmacol
<volume>3</volume>: <fpage>128</fpage>, <year>2012</year><pub-id pub-id-type="pmid">22783192</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>AR</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Segal</surname><given-names>AW</given-names></name></person-group>
<article-title>The NADPH oxidase of professional phagocytes—prototype of the NOX electron transport chain systems</article-title>. <source/>Biochim Biophys Acta
<volume>1657</volume>: <fpage>1</fpage>–<lpage>22</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15238208</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cucoranu</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Clempus</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dikalova</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Phelan</surname><given-names>PJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ariyan</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sorescu</surname><given-names>D</given-names></name></person-group>
<article-title>NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts</article-title>. <source/>Circ Res
<volume>97</volume>: <fpage>900</fpage>–<lpage>907</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16179589</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derbyshire</surname><given-names>ER</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Marletta</surname><given-names>MA</given-names></name></person-group>
<article-title>Structure and regulation of soluble guanylate cyclase</article-title>. <source/>Annu Rev Biochem
<volume>81</volume>: <fpage>533</fpage>–<lpage>559</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22404633</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kaludercic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carpi</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Menabo</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>M</given-names></name></person-group>
<article-title>Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase</article-title>. <source/>Basic Res Cardiol
<volume>104</volume>: <fpage>131</fpage>–<lpage>139</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19242637</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikalova</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Clempus</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lassegue</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McCoy</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>San Martin</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lyle</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weber</surname><given-names>DS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weiss</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taylor</surname><given-names>WR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Owens</surname><given-names>GK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lambeth</surname><given-names>JD</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Griendling</surname><given-names>KK</given-names></name></person-group>
<article-title>Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice</article-title>. <source/>Circulation
<volume>112</volume>: <fpage>2668</fpage>–<lpage>2676</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16230485</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Droge</surname><given-names>W.</given-names></name></person-group>
<article-title>Free radicals in the physiological control of cell function</article-title>. <source/>Physiol Rev
<volume>82</volume>: <fpage>47</fpage>–<lpage>95</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11773609</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmondson</surname><given-names>DE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mattevi</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Binda</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hubalek</surname><given-names>F</given-names></name></person-group>
<article-title>Structure and mechanism of monoamine oxidase</article-title>. <source/>Curr Med Chem
<volume>11</volume>: <fpage>1983</fpage>–<lpage>1993</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15279562</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiserich</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baldus</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brennan</surname><given-names>ML</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tousson</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Castro</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nauseef</surname><given-names>WM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>White</surname><given-names>CR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group>
<article-title>Myeloperoxidase, a leukocyte-derived vascular NO oxidase</article-title>. <source/>Science
<volume>296</volume>: <fpage>2391</fpage>–<lpage>2394</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12089442</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elion</surname><given-names>GB.</given-names></name></person-group>
<article-title>The purine path to chemotherapy</article-title>. <source/>Science
<volume>244</volume>: <fpage>41</fpage>–<lpage>47</lpage>, <year>1989</year><pub-id pub-id-type="pmid">2649979</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evgenov</surname><given-names>OV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hasko</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name></person-group>
<article-title>NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</article-title>. <source/>Nat Rev Drug Discov
<volume>5</volume>: <fpage>755</fpage>–<lpage>768</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16955067</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Alderman</surname><given-names>MH</given-names></name></person-group>
<article-title>Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey</article-title>. <source/>JAMA
<volume>283</volume>: <fpage>2404</fpage>–<lpage>2410</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10815083</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fini</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Monks</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Farabaugh</surname><given-names>SM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wright</surname><given-names>RM</given-names></name></person-group>
<article-title>Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1</article-title>. <source/>Mol Cancer Res
<volume>9</volume>: <fpage>1242</fpage>–<lpage>1254</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21775420</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>38a.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frijhoff J</surname><given-names>WPG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cheng</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Davies</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knight</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taylor</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ruskovska</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gasparovic</surname><given-names>AC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oettrich</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zarkovic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weber</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grune</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Clinical relevance of biomarkers of oxidative stress</article-title>. <source/>Antioxid Redox Signal
<volume>23</volume>: <fpage>1144</fpage>–<lpage>1170</lpage>, <year>2015</year><pub-id pub-id-type="pmid">26415143</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulton</surname><given-names>DJ.</given-names></name></person-group>
<article-title>Nox5 and the regulation of cellular function</article-title>. <source/>Antioxid Redox Signal
<volume>11</volume>: <fpage>2443</fpage>–<lpage>2452</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19331545</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlong</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ho</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>JS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Walsh</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Paykel</surname><given-names>ES</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name></person-group>
<article-title>Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter</article-title>. <source/>Am J Med Genet
<volume>88</volume>: <fpage>398</fpage>–<lpage>406</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10402508</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaut</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Byun</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tran</surname><given-names>HD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lauber</surname><given-names>WM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belaaouaj</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>
<article-title>Myeloperoxidase produces nitrating oxidants in vivo</article-title>. <source/>J Clin Invest
<volume>109</volume>: <fpage>1311</fpage>–<lpage>1319</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12021246</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavazzi</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Banfi</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deffert</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fiette</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schappi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>Decreased blood pressure in NOX1-deficient mice</article-title>. <source/>FEBS Lett
<volume>580</volume>: <fpage>497</fpage>–<lpage>504</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16386251</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavazzi</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deffert</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Trocme</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schappi</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>FR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>NOX1 deficiency protects from aortic dissection in response to angiotensin II</article-title>. <source/>Hypertension
<volume>50</volume>: <fpage>189</fpage>–<lpage>196</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17502491</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gheorghiade</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Greene</surname><given-names>SJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Filippatos</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Erdmann</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Levy</surname><given-names>PD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maggioni</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nowack</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Mebazaa</surname><given-names>A</given-names></name></person-group>
<article-title>Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes</article-title>. <source/>Eur J Heart Fail
<volume>14</volume>: <fpage>1056</fpage>–<lpage>1066</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22713287</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Galie</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grimminger</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grunig</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Humbert</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jing</surname><given-names>ZC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Keogh</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Langleben</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kilama</surname><given-names>MO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fritsch</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neuser</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Rubin</surname><given-names>LJ</given-names></name></person-group>
<article-title>Riociguat for the treatment of pulmonary arterial hypertension</article-title>. <source/>N Engl J Med
<volume>369</volume>: <fpage>330</fpage>–<lpage>340</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23883378</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Givertz</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Anstrom</surname><given-names>KJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Redfield</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deswal</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haddad</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Butler</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tang</surname><given-names>WH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dunlap</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>LeWinter</surname><given-names>MM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mann</surname><given-names>DL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Felker</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>CM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Goldsmith</surname><given-names>SR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ofili</surname><given-names>EO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Saltzberg</surname><given-names>MT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Margulies</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cappola</surname><given-names>TP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Konstam</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Semigran</surname><given-names>MJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McNulty</surname><given-names>SE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lee</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shah</surname><given-names>MR</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>AF</given-names></name></person-group>
<article-title>Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study</article-title>. <source/>Circulation
<volume>131</volume>: <fpage>1763</fpage>–<lpage>1771</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25986447</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>46a.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goettsch</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Babelova</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Trummer</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Erben</surname><given-names>RG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rauner</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rammelt</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Benkhoff</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kampschulte</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Obermayer-Pietsch</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hofbauer</surname><given-names>LC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name></person-group>
<article-title>NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis</article-title>. <source/>J Clin Invest
<volume>123</volume>: <fpage>4731</fpage>–<lpage>4738</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24216508</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gori</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Burstein</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miner</surname><given-names>SE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Al-Hesayen</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kelly</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Parker</surname><given-names>JD</given-names></name></person-group>
<article-title>Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study</article-title>. <source/>Circulation
<volume>104</volume>: <fpage>1119</fpage>–<lpage>1123</lpage>., <year>2001</year><pub-id pub-id-type="pmid">11535566</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>SP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Okabe</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Szyndralewiez</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heitz</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Montezano</surname><given-names>AC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de Haan</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Koulis</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>El-Osta</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andrews</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chin-Dusting</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Jandeleit-Dahm</surname><given-names>KA</given-names></name></person-group>
<article-title>NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis</article-title>. <source/>Circulation
<volume>127</volume>: <fpage>1888</fpage>–<lpage>1902</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23564668</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gongora</surname><given-names>MC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guzik</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lob</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mangalat</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoch</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rudzinski</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kapelak</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sadowski</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group>
<article-title>Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease</article-title>. <source/>J Am Coll Cardiol
<volume>52</volume>: <fpage>1803</fpage>–<lpage>1809</lpage>, <year>2008</year><pub-id pub-id-type="pmid">19022160</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampton</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kettle</surname><given-names>AJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group>
<article-title>Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing</article-title>. <source/>Blood
<volume>92</volume>: <fpage>3007</fpage>–<lpage>3017</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9787133</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kharitonov</surname><given-names>SA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>LE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Erin</surname><given-names>EM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Currie</surname><given-names>MG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Moore</surname><given-names>WM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Manning</surname><given-names>PT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Recker</surname><given-names>DP</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group>
<article-title>A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics</article-title>. <source/>FASEB J
<volume>17</volume>: <fpage>1298</fpage>–<lpage>1300</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12738811</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Logsdon</surname><given-names>NJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kurundkar</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kurundkar</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bernard</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hock</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meldrum</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sanders</surname><given-names>YY</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>VJ</given-names></name></person-group>
<article-title>Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance</article-title>. <source/>Sci Transl Med
<volume>6</volume>: <fpage>231ra47</fpage>, <year>2014</year></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vittal</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jones</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jagirdar</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Luckhardt</surname><given-names>TR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pennathur</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>VJ</given-names></name></person-group>
<article-title>NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</article-title>. <source/>Nat Med
<volume>15</volume>: <fpage>1077</fpage>–<lpage>1081</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19701206</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitzer</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brockhoff</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mayer</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Warnholtz</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mollnau</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Henne</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>
<article-title>Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase</article-title>. <source/>Circ Res
<volume>86</volume>: <fpage>E36</fpage>–<lpage>E41</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10666424</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitzer</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Krohn</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Albers</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>
<article-title>Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus</article-title>. <source/>Diabetologia
<volume>43</volume>: <fpage>1435</fpage>–<lpage>1438</lpage>, <year>2000</year><pub-id pub-id-type="pmid">11126415</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heumuller</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wind</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barbosa-Sicard</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Busse</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group>
<article-title>Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant</article-title>. <source/>Hypertension
<volume>51</volume>: <fpage>211</fpage>–<lpage>217</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18086956</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hille</surname><given-names>R</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Nishino</surname><given-names>T</given-names></name></person-group>
<article-title>Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase</article-title>. <source/>FASEB J
<volume>9</volume>: <fpage>995</fpage>–<lpage>1003</lpage>, <year>1995</year><pub-id pub-id-type="pmid">7649415</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>YC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Janczuk</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wang</surname><given-names>PG</given-names></name></person-group>
<article-title>Current trends in the development of nitric oxide donors</article-title>. <source/>Curr Pharm Des
<volume>5</volume>: <fpage>417</fpage>–<lpage>441</lpage>, <year>1999</year><pub-id pub-id-type="pmid">10390607</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hultqvist</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Olsson</surname><given-names>LM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gelderman</surname><given-names>KA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Holmdahl</surname><given-names>R</given-names></name></person-group>
<article-title>The protective role of ROS in autoimmune disease</article-title>. <source/>Trends Immunol
<volume>30</volume>: <fpage>201</fpage>–<lpage>208</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19356981</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gray</surname><given-names>SP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barit</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Okabe</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>El-Osta</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Namikoshi</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thallas-Bonke</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Szyndralewiez</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heitz</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Jandeleit-Dahm</surname><given-names>KA</given-names></name></person-group>
<article-title>Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy</article-title>. <source/>J Am Soc Nephrol
<volume>25</volume>: <fpage>1237</fpage>–<lpage>1254</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24511132</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marden</surname><given-names>CC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ward-Bailey</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>LH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bronson</surname><given-names>RT</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Donahue</surname><given-names>LR</given-names></name></person-group>
<article-title>Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2</article-title>. <source/>Mol Endocrinol
<volume>21</volume>: <fpage>1593</fpage>–<lpage>1602</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17440044</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaludercic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Carpi</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nagayama</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sivakumaran</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lai</surname><given-names>EW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bedja</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>De Mario</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gabrielson</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>ML</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pacak</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Takimoto</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kass</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Paolocci</surname><given-names>N</given-names></name></person-group>
<article-title>Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts</article-title>. <source/>Antioxid Redox Signal
<volume>20</volume>: <fpage>267</fpage>–<lpage>280</lpage>, <year>2014</year><pub-id pub-id-type="pmid">23581564</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaludercic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deshwal</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>
<article-title>Reactive oxygen species and redox compartmentalization</article-title>. <source/>Front Physiol
<volume>5</volume>: <fpage>285</fpage>, <year>2014</year><pub-id pub-id-type="pmid">25161621</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaludercic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mialet-Perez</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Paolocci</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parini</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>
<article-title>Monoamine oxidases as sources of oxidants in the heart</article-title>. <source/>J Mol Cell Cardiol
<volume>73</volume>: <fpage>34</fpage>–<lpage>42</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24412580</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaludercic</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Takimoto</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nagayama</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feng</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lai</surname><given-names>EW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bedja</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gabrielson</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blakely</surname><given-names>RD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pacak</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kass</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Paolocci</surname><given-names>N</given-names></name></person-group>
<article-title>Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload</article-title>. <source/>Circ Res
<volume>106</volume>: <fpage>193</fpage>–<lpage>202</lpage>, <year>2010</year><pub-id pub-id-type="pmid">19910579</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scott</surname><given-names>WK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>YJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hauser</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van der Walt</surname><given-names>JM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mayhew</surname><given-names>GM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>West</surname><given-names>SG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vance</surname><given-names>JM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Martin</surname><given-names>ER</given-names></name></person-group>
<article-title>Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson disease</article-title>. <source/>Mov Disord
<volume>21</volume>: <fpage>2175</fpage>–<lpage>2180</lpage>, <year>2006</year><pub-id pub-id-type="pmid">17044053</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kareyeva</surname><given-names>AV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grivennikova</surname><given-names>VG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cecchini</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Vinogradov</surname><given-names>AD</given-names></name></person-group>
<article-title>Molecular identification of the enzyme responsible for the mitochondrial NADH-supported ammonium-dependent hydrogen peroxide production</article-title>. <source/>FEBS Lett
<volume>585</volume>: <fpage>385</fpage>–<lpage>389</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21168410</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawahara</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Quinn</surname><given-names>MT</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lambeth</surname><given-names>JD</given-names></name></person-group>
<article-title>Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes</article-title>. <source/>BMC Evol Biol
<volume>7</volume>: <fpage>109</fpage>, <year>2007</year><pub-id pub-id-type="pmid">17612411</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>PJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knisz</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baltrusaitis</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sigmund</surname><given-names>CD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thalmann</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Smith</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Verpy</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Banfi</surname><given-names>B</given-names></name></person-group>
<article-title>Inactivation of NADPH oxidase organizer 1 results in severe imbalance</article-title>. <source/>Curr Biol
<volume>16</volume>: <fpage>208</fpage>–<lpage>213</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16431374</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klebanoff</surname><given-names>SJ.</given-names></name></person-group>
<article-title>Myeloperoxidase-halide-hydrogen peroxide antibacterial system</article-title>. <source/>J Bacteriol
<volume>95</volume>: <fpage>2131</fpage>–<lpage>2138</lpage>, <year>1968</year><pub-id pub-id-type="pmid">4970226</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klebanoff</surname><given-names>SJ.</given-names></name></person-group>
<article-title>Oxygen metabolism and the toxic properties of phagocytes</article-title>. <source/>Ann Intern Med
<volume>93</volume>: <fpage>480</fpage>–<lpage>489</lpage>, <year>1980</year><pub-id pub-id-type="pmid">6254418</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleikers</surname><given-names>PW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hermans</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Diebold</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Altenhofer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Radermacher</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Janssen</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gorlach</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury</article-title>. <source/>J Mol Med (Berl)
<volume>90</volume>: <fpage>1391</fpage>–<lpage>1406</lpage>, <year>2012</year><pub-id pub-id-type="pmid">23090009</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grund</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Armitage</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jones</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mittal</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barit</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Geis</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kraft</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Barthel</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schuhmann</surname><given-names>MK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meuth</surname><given-names>SG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stoll</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meurer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schrewe</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Becker</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gailus-Durner</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klopstock</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de Angelis</surname><given-names>MH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jandeleit-Dahm</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shah</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration</article-title>. <source/>PLoS Biol
<volume>8</volume>: pii: <!--<pub-id pub-id-type="pii">e1000479</pub-id>-->, <year>2010</year></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>LT</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Klann</surname><given-names>E</given-names></name></person-group>
<article-title>Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content</article-title>. <source/>J Biol Chem
<volume>275</volume>: <fpage>24136</fpage>–<lpage>24145</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10823825</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korichneva</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoyos</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chua</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Levi</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hammerling</surname><given-names>U</given-names></name></person-group>
<article-title>Zinc release from protein kinase C as the common event during activation by lipid second messenger or reactive oxygen</article-title>. <source/>J Biol Chem
<volume>277</volume>: <fpage>44327</fpage>–<lpage>44331</lpage>, <year>2002</year><pub-id pub-id-type="pmid">12213816</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lambeth</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Kronke</surname><given-names>M</given-names></name></person-group>
<article-title>NOX enzymes as drug targets</article-title>. <source/>Cell Mol Life Sci
<volume>69</volume>: <fpage>2279</fpage>–<lpage>2282</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22585058</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreatsoulas</surname><given-names>C</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Anand</surname><given-names>SS</given-names></name></person-group>
<article-title>The impact of social determinants on cardiovascular disease</article-title>. <source/>Can J Cardiol
<volume>26</volume>
<issue>Suppl C</issue>: <fpage>8c</fpage>–<lpage>13c</lpage>, <year>2010</year></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>PA.</given-names></name></person-group>
<article-title>A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?</article-title>
<source/>Expert Opin Pharmacother
<volume>11</volume>: <fpage>1753</fpage>–<lpage>1763</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20491547</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mollnau</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eiserich</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daiber</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gehling</surname><given-names>UM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brummer</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heitzer</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Baldus</surname><given-names>S</given-names></name></person-group>
<article-title>Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>102</volume>: <fpage>431</fpage>–<lpage>436</lpage>, <year>2005</year><pub-id pub-id-type="pmid">15625114</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laursen</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Somers</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kurz</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>McCann</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Warnholtz</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tarpey</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fukai</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group>
<article-title>Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin</article-title>. <source/>Circulation
<volume>103</volume>: <fpage>1282</fpage>–<lpage>1288</lpage>, <year>2001</year><pub-id pub-id-type="pmid">11238274</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leto</surname><given-names>TL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morand</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hurt</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ueyama</surname><given-names>T</given-names></name></person-group>
<article-title>Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases</article-title>. <source/>Antioxid Redox Signal
<volume>11</volume>: <fpage>2607</fpage>–<lpage>2619</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19438290</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guan</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group>
<article-title>The monoamine oxidase B gene exhibits significant association to ADHD</article-title>. <source/>Am J Med Genet B Neuropsychiatr Genet
<volume>147</volume>: <fpage>370</fpage>–<lpage>374</lpage>, <year>2008</year><pub-id pub-id-type="pmid">17918234</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>LC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Powell</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sham</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Castle</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hunt</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Murray</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Gill</surname><given-names>M</given-names></name></person-group>
<article-title>Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder</article-title>. <source/>Am J Med Genet
<volume>60</volume>: <fpage>325</fpage>–<lpage>331</lpage>, <year>1995</year><pub-id pub-id-type="pmid">7485270</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>VW</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Huang</surname><given-names>PL</given-names></name></person-group>
<article-title>Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice</article-title>. <source/>Cardiovasc Res
<volume>77</volume>: <fpage>19</fpage>–<lpage>29</lpage>, <year>2008</year><pub-id pub-id-type="pmid">17658499</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>J</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Chiu</surname><given-names>E</given-names></name></person-group>
<article-title>Platelet monoamine oxidase activity in Huntington's chorea</article-title>. <source/>J Neurol Neurosurg Psychiatry
<volume>41</volume>: <fpage>809</fpage>–<lpage>812</lpage>, <year>1978</year><pub-id pub-id-type="pmid">151126</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martyn</surname><given-names>KD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Frederick</surname><given-names>LM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>von Loehneysen</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dinauer</surname><given-names>MC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Knaus</surname><given-names>UG</given-names></name></person-group>
<article-title>Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases</article-title>. <source/>Cell Signal
<volume>18</volume>: <fpage>69</fpage>–<lpage>82</lpage>, <year>2006</year><pub-id pub-id-type="pmid">15927447</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuno</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yamada</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Iwata</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jin</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Katsuyama</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matsuki</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Takai</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yamanishi</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>H</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yabe-Nishimura</surname><given-names>C</given-names></name></person-group>
<article-title>Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice</article-title>. <source/>Circulation
<volume>112</volume>: <fpage>2677</fpage>–<lpage>2685</lpage>, <year>2005</year><pub-id pub-id-type="pmid">16246966</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurel</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kunduzova</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bompart</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cambon</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parini</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Frances</surname><given-names>B</given-names></name></person-group>
<article-title>Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats</article-title>. <source/>Am J Physiol Heart Circ Physiol
<volume>284</volume>: <fpage>H1460</fpage>–<lpage>H1467</lpage>, <year>2003</year><pub-id pub-id-type="pmid">12531732</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCord</surname><given-names>JM.</given-names></name></person-group>
<article-title>Oxygen-derived free radicals in postischemic tissue injury</article-title>. <source/>N Engl J Med
<volume>312</volume>: <fpage>159</fpage>–<lpage>163</lpage>, <year>1985</year><pub-id pub-id-type="pmid">2981404</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melichar</surname><given-names>VO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Behr-Roussel</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zabel</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Uttenthal</surname><given-names>LO</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodrigo</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rupin</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Verbeuren</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kumar</surname><given-names>HSA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>101</volume>: <fpage>16671</fpage>–<lpage>16676</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15546990</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menazza</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blaauw</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tiepolo</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Toniolo</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Braghetta</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Spolaore</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reggiani</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Di Lisa</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bonaldo</surname><given-names>P</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Canton</surname><given-names>M</given-names></name></person-group>
<article-title>Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy</article-title>. <source/>Hum Mol Genet
<volume>19</volume>: <fpage>4207</fpage>–<lpage>4215</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20716577</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meurer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pioch</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pabst</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Opitz</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beckhaus</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wagner</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matt</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gegenbauer</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Geschka</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karas</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Muller-Esterl</surname><given-names>W</given-names></name></person-group>
<article-title>Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation</article-title>. <source/>Circ Res
<volume>105</volume>: <fpage>33</fpage>–<lpage>41</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19478201</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Martasek</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roman</surname><given-names>LJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>JS</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Masters</surname><given-names>BS</given-names></name></person-group>
<article-title>Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production</article-title>. <source/>Biochemistry
<volume>36</volume>: <fpage>15277</fpage>–<lpage>15284</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9398256</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roth</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Konig</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dony</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Goyal</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Selbitz</surname><given-names>AC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schermuly</surname><given-names>RT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kwapiszewska</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kummer</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klepetko</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoda</surname><given-names>MA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fink</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hanze</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Seeger</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Grimminger</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>N</given-names></name></person-group>
<article-title>Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature</article-title>. <source/>Circ Res
<volume>101</volume>: <fpage>258</fpage>–<lpage>267</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17585072</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montezano</surname><given-names>AC</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group>
<article-title>Reactive oxygen species and endothelial function—role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases</article-title>. <source/>Basic Clin Pharmacol Toxicol
<volume>110</volume>: <fpage>87</fpage>–<lpage>94</lpage>, <year>2012</year><pub-id pub-id-type="pmid">21883939</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ohtsubo</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kansui</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Goto</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Haga</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakabeppu</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Kitazono</surname><given-names>T</given-names></name></person-group>
<article-title>Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes</article-title>. <source/>Arterioscler Thromb Vasc Biol
<volume>34</volume>: <fpage>44</fpage>–<lpage>51</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24158515</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>DL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sims</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karoum</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de la Chapelle</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Norio</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sankila</surname><given-names>EM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Breakefield</surname><given-names>XO</given-names></name></person-group>
<article-title>Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase</article-title>. <source/>J Neurochem
<volume>54</volume>: <fpage>242</fpage>–<lpage>247</lpage>, <year>1990</year><pub-id pub-id-type="pmid">2293615</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>T.</given-names></name></person-group>
<article-title>The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene</article-title>. <source/>J Biol Chem
<volume>272</volume>: <fpage>29859</fpage>–<lpage>29864</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9368059</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nisimoto</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Diebold</surname><given-names>BA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Constentino-Gomes</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lambeth</surname><given-names>JD</given-names></name></person-group>
<article-title>Nox4: a hydrogen peroxide-generating oxygen sensor</article-title>. <source/>Biochemistry
<volume>53</volume>: <fpage>5111</fpage>–<lpage>5120</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25062272</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nlandu Khodo</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dizin</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sossauer</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Szanto</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Martin</surname><given-names>PY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Feraille</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>de Seigneux</surname><given-names>S</given-names></name></person-group>
<article-title>NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury</article-title>. <source/>J Am Soc Nephrol
<volume>23</volume>: <fpage>1967</fpage>–<lpage>1976</lpage>, <year>2012</year><pub-id pub-id-type="pmid">23100220</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odobasic</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kitching</surname><given-names>AR</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>KM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muljadi</surname><given-names>RC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Edgtton</surname><given-names>KL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tan</surname><given-names>DS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Summers</surname><given-names>SA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morand</surname><given-names>EF</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Holdsworth</surname><given-names>SR</given-names></name></person-group>
<article-title>Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function</article-title>. <source/>Blood
<volume>121</volume>: <fpage>4195</fpage>–<lpage>4204</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23509155</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullen</surname><given-names>SS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lincoln</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harrison</surname><given-names>PC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Clifford</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Qian</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wong</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sarko</surname><given-names>C</given-names></name></person-group>
<person-group person-group-type="author"><name><surname>Brenneman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fryer</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Richman</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Reinhart</surname><given-names>GA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Boustany</surname><given-names>C.</given-names></name></person-group>
<article-title>A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat</article-title>. <source/>BMC Pharmacology and Toxicology
<year>2015</year>
<volume>16</volume>(<issue>Suppl</issue>): <fpage>A4</fpage></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paffenholz</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bergstrom</surname><given-names>RA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pasutto</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wabnitz</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Munroe</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jagla</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heinzmann</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bareiss</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Laufs</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Russ</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stumm</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schimenti</surname><given-names>JC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bergstrom</surname><given-names>DE</given-names></name></person-group>
<article-title>Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase</article-title>. <source/>Genes Dev
<volume>18</volume>: <fpage>486</fpage>–<lpage>491</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15014044</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peskin</surname><given-names>AV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Midwinter</surname><given-names>RG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Harwood</surname><given-names>DT</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group>
<article-title>Chlorine transfer between glycine, taurine, and histamine: reaction rates and impact on cellular reactivity</article-title>. <source/>Free Radic Biol Med
<volume>37</volume>: <fpage>1622</fpage>–<lpage>1630</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15477013</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieske</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Butler</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Filippatos</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lam</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maggioni</surname><given-names>AP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shah</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Solomon</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kraigher-Krainer</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Samano</surname><given-names>ET</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scalise</surname><given-names>AV</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muller</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Roessig</surname><given-names>L</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Gheorghiade</surname><given-names>M</given-names></name></person-group>
<article-title>Rationale and design of the SOluble guanylate cyclase stimulatoR in heArT failurE Studies (SOCRATES)</article-title>. <source/>Eur J Heart Fail
<volume>16</volume>: <fpage>1026</fpage>–<lpage>1038</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25056511</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piret</surname><given-names>SE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Esapa</surname><given-names>CT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gorvin</surname><given-names>CM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Head</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loh</surname><given-names>NY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Devuyst</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thomas</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>SD</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Croucher</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cox</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Thakker</surname><given-names>RV</given-names></name></person-group>
<article-title>A mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutation</article-title>. <source/>PLoS One
<volume>7</volume>: <fpage>e45217</fpage>, <year>2012</year><pub-id pub-id-type="pmid">23024809</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podrez</surname><given-names>EA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Abu-Soud</surname><given-names>HM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group>
<article-title>Myeloperoxidase-generated oxidants and atherosclerosis</article-title>. <source/>Free Radic Biol Med
<volume>28</volume>: <fpage>1717</fpage>–<lpage>1725</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10946213</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bharti</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Majeed</surname><given-names>AB</given-names></name></person-group>
<article-title>Zinc: indications in brain disorders</article-title>. <source/>Fundam Clin Pharmacol
<volume>29</volume>: <fpage>131</fpage>–<lpage>149</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25659970</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radermacher</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleikers</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Altenhofer</surname><given-names>S</given-names><suffix>Jr.</suffix></name></person-group>, <person-group person-group-type="author"><name><surname>Hermans</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hhw Schmidt</surname><given-names>H.</given-names></name></person-group>
<article-title>The 1027th target candidate in stroke: will NADPH oxidase hold up?</article-title>
<source/>Exp Transl Stroke Med
<volume>4</volume>: <fpage>11</fpage>, <year>2012</year><pub-id pub-id-type="pmid">22625431</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radermacher</surname><given-names>KA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Langhauser</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Altenhofer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleikers</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hermans</surname><given-names>JJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hrabe de Angelis</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress</article-title>. <source/>Antioxid Redox Signal
<volume>18</volume>: <fpage>1418</fpage>–<lpage>1427</lpage>, <year>2013</year><pub-id pub-id-type="pmid">22937798</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>RR</given-names></name></person-group>
<article-title>Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery</article-title>. <source/>Curr Top Med Chem
<volume>12</volume>: <fpage>2189</fpage>–<lpage>2209</lpage>, <year>2012</year><pub-id pub-id-type="pmid">23231396</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribases</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ramos-Quiroga</surname><given-names>JA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hervas</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bosch</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bielsa</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gastaminza</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Artigas</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodriguez-Ben</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Estivill</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Casas</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cormand</surname><given-names>B</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Bayes</surname><given-names>M</given-names></name></person-group>
<article-title>Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB</article-title>. <source/>Mol Psychiatry
<volume>14</volume>: <fpage>71</fpage>–<lpage>85</lpage>, <year>2009</year><pub-id pub-id-type="pmid">17938636</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Munoz</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de la Torre-Madrid</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sanchez-Blazquez</surname><given-names>P</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Garzon</surname><given-names>J</given-names></name></person-group>
<article-title>NO-released zinc supports the simultaneous binding of Raf-1 and PKCgamma cysteine-rich domains to HINT1 protein at the mu-opioid receptor</article-title>. <source/>Antioxid Redox Signal
<volume>14</volume>: <fpage>2413</fpage>–<lpage>2425</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21235400</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinsztein</surname><given-names>DC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leggo</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Goodburn</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Walsh</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Paykel</surname><given-names>ES</given-names></name></person-group>
<article-title>Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis</article-title>. <source/>Hum Mol Genet
<volume>5</volume>: <fpage>779</fpage>–<lpage>782</lpage>, <year>1996</year><pub-id pub-id-type="pmid">8776592</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>TK</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Witte</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klinke</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Szoecs</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lau</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Heitzer</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Baldus</surname><given-names>S</given-names></name></person-group>
<article-title>Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function</article-title>. <source/>Int J Cardiol
<volume>140</volume>: <fpage>42</fpage>–<lpage>47</lpage>, <year>2008</year><pub-id pub-id-type="pmid">19049846</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Blazquez</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rodriguez-Munoz</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bailon</surname><given-names>C</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Garzon</surname><given-names>J</given-names></name></person-group>
<article-title>GPCRs promote the release of zinc ions mediated by nNOS/NO and the redox transducer RGSZ2 protein</article-title>. <source/>Antioxid Redox Signal
<volume>17</volume>: <fpage>1163</fpage>–<lpage>1177</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22563771</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Glover</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Clow</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Jarman</surname><given-names>J</given-names></name></person-group>
<article-title>Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?</article-title>
<source/>Adv Neurol
<volume>60</volume>: <fpage>238</fpage>–<lpage>241</lpage>, <year>1993</year><pub-id pub-id-type="pmid">8420141</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saura</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andres</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Andrade</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ojuel</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Mahy</surname><given-names>N</given-names></name></person-group>
<article-title>Biphasic and region-specific MAO-B response to aging in normal human brain</article-title>. <source/>Neurobiol Aging
<volume>18</volume>: <fpage>497</fpage>–<lpage>507</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9390776</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savenkova</surname><given-names>ML</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mueller</surname><given-names>DM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group>
<article-title>Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein</article-title>. <source/>J Biol Chem
<volume>269</volume>: <fpage>20394</fpage>–<lpage>20400</lpage>, <year>1994</year><pub-id pub-id-type="pmid">8051134</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schappi</surname><given-names>MG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jaquet</surname><given-names>V</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belli</surname><given-names>DC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase</article-title>. <source/>Semin Immunopathol
<volume>30</volume>: <fpage>255</fpage>–<lpage>271</lpage>, <year>2008</year><pub-id pub-id-type="pmid">18509648</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schieber</surname><given-names>M</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group>
<article-title>ROS function in redox signaling and oxidative stress</article-title>. <source/>Curr Biol
<volume>24</volume>: <fpage>R453</fpage>–<lpage>R462</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24845678</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vollbracht</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Paulsen</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Riley</surname><given-names>DP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Daiber</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>A</given-names></name></person-group>
<article-title>Antioxidants in Translational Medicine</article-title>. <source/>Antioxid Redox Signal
<volume>23</volume>: <fpage>1130</fpage>–<lpage>1143</lpage>, <year>2015</year><pub-id pub-id-type="pmid">26154592</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>122a.</label>
<mixed-citation publication-type="journal">This reference has been deleted.</mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Walter</surname><given-names>U</given-names></name></person-group>
<article-title>NO at work</article-title>. <source/>Cell
<volume>78</volume>: <fpage>919</fpage>–<lpage>925</lpage>, <year>1994</year><pub-id pub-id-type="pmid">7923361</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vecchione</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jung</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>JG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shiri-Sverdlov</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>van Gorp</surname><given-names>PJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Busse</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group>
<article-title>Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet</article-title>. <source/>Free Radic Biol Med
<volume>41</volume>: <fpage>1353</fpage>–<lpage>1360</lpage>, <year>2006</year><pub-id pub-id-type="pmid">17023262</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuhmacher</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schulz</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oelze</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mang</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kamuf</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gori</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jansen</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knorr</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Karbach</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hortmann</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mathner</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bhatnagar</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forstermann</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Daiber</surname><given-names>A</given-names></name></person-group>
<article-title>Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1</article-title>. <source/>Hypertension
<volume>55</volume>: <fpage>897</fpage>–<lpage>904</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20157049</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>125a.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Daiber</surname><given-names>A</given-names></name></person-group>
<article-title>Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress</article-title>. <source/>Antioxid Redox Signal
<volume>20</volume>: <fpage>308</fpage>–<lpage>324</lpage>, <year>2014</year><pub-id pub-id-type="pmid">22657349</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrander</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cartier</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bedard</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Banfi</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lardy</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Plastre</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sienkiewicz</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Forro</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schlegel</surname><given-names>W</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Krause</surname><given-names>KH</given-names></name></person-group>
<article-title>NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation</article-title>. <source/>Biochem J
<volume>406</volume>: <fpage>105</fpage>–<lpage>114</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17501721</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>KB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>de la Chapelle</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Norio</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sankila</surname><given-names>EM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hsu</surname><given-names>YP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rinehart</surname><given-names>WB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Corey</surname><given-names>TJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ozelius</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Powell</surname><given-names>JF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bruns</surname><given-names>G</given-names></name>, <etal><italic>et al.</italic></etal></person-group>
<article-title>Monoamine oxidase deficiency in males with an X chromosome deletion</article-title>. <source/>Neuron
<volume>2</volume>: <fpage>1069</fpage>–<lpage>1076</lpage>, <year>1989</year><pub-id pub-id-type="pmid">2483108</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bortolato</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bali</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Godar</surname><given-names>SC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scott</surname><given-names>AL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Thompson</surname><given-names>RF</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>
<article-title>Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>110</volume>: <fpage>12816</fpage>–<lpage>12821</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23858446</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dembowsky</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Perzborn</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stahl</surname><given-names>E</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schramm</surname><given-names>M</given-names></name></person-group>
<article-title>Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543: in vivo studies</article-title>. <source/>Br J Pharmacol
<volume>135</volume>: <fpage>344</fpage>–<lpage>355</lpage>, <year>2002</year><pub-id pub-id-type="pmid">11815369</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schlossmann</surname><given-names>J</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Hocher</surname><given-names>B</given-names></name></person-group>
<article-title>Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence</article-title>. <source/>Curr Opin Pharmacol
<volume>21c</volume>: <fpage>95</fpage>–<lpage>104</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25645316</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nedvetsky</surname><given-names>PI</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nedvetskaya</surname><given-names>TY</given-names></name></person-group> H S AK, <person-group person-group-type="author"><name><surname>Meurer</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deile</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taye</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knorr</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lapp</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muller</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Turgay</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rothkegel</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tersteegen</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kemp-Harper</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muller-Esterl</surname><given-names>W</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels</article-title>. <source/>J Clin Invest
<volume>116</volume>: <fpage>2552</fpage>–<lpage>2561</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16955146</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhubl</surname><given-names>SR</given-names></name></person-group>
<article-title>Why have antioxidants failed in clinical trials?</article-title>
<source/>Am J Cardiol
<volume>101</volume>: <fpage>14d</fpage>–<lpage>19d</lpage>, <year>2008</year></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stover</surname><given-names>JF</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Belli</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boret</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Bulters</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sahuquillo</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmutzhard</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zavala</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ungerstedt</surname><given-names>U</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schinzel</surname><given-names>R</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Tegtmeier</surname><given-names>F</given-names></name></person-group>
<article-title>Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA)</article-title>. <source/>J Neurotrauma
<volume>31</volume>: <fpage>1599</fpage>–<lpage>1606</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24831445</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturza</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Leisegang</surname><given-names>MS</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Babelova</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Benkhoff</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loot</surname><given-names>AE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Fleming</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muntean</surname><given-names>DM</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group>
<article-title>Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta</article-title>. <source/>Hypertension
<volume>62</volume>: <fpage>140</fpage>–<lpage>146</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23670301</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>DeLano</surname><given-names>FA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parks</surname><given-names>DA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jamshidi</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Granger</surname><given-names>DN</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Suematsu</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zweifach</surname><given-names>BW</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmid-Schonbein</surname><given-names>GW</given-names></name></person-group>
<article-title>Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>95</volume>: <fpage>4754</fpage>–<lpage>4759</lpage>, <year>1998</year><pub-id pub-id-type="pmid">9539811</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sydow</surname><given-names>K</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Munzel</surname><given-names>T</given-names></name></person-group>
<article-title>ADMA and oxidative stress</article-title>. <source/>Atheroscler Suppl
<volume>4</volume>: <fpage>41</fpage>–<lpage>51</lpage>, <year>2003</year><pub-id pub-id-type="pmid">14664902</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thanan</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Oikawa</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hiraku</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ohnishi</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ma</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pinlaor</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yongvanit</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kawanishi</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Murata</surname><given-names>M</given-names></name></person-group>
<article-title>Oxidative stress and its significant roles in neurodegenerative diseases and cancer</article-title>. <source/>Int J Mol Sci
<volume>16</volume>: <fpage>193</fpage>–<lpage>217</lpage>, <year>2014</year><pub-id pub-id-type="pmid">25547488</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsui</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shimokawa</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Morishita</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>Y</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Yanagihara</surname><given-names>N</given-names></name></person-group>
<article-title>Development of genetically engineered mice lacking all three nitric oxide synthases</article-title>. <source/>J Pharmacol Sci
<volume>102</volume>: <fpage>147</fpage>–<lpage>154</lpage>, <year>2006</year><pub-id pub-id-type="pmid">17031076</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Schueren</surname><given-names>BJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lunnon</surname><given-names>MW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Laurijssens</surname><given-names>BE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guillard</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Palmer</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Van Hecken</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Depre</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Vanmolkot</surname><given-names>FH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>de Hoon</surname><given-names>JN</given-names></name></person-group>
<article-title>Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?</article-title>
<source/>J Clin Pharmacol
<volume>49</volume>: <fpage>281</fpage>–<lpage>290</lpage>, <year>2009</year><pub-id pub-id-type="pmid">19246728</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villeneuve</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Guilbeau-Frugier</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Sicard</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lairez</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ordener</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Duparc</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>De Paulis</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Couderc</surname><given-names>B</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Spreux-Varoquaux</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tortosa</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Garnier</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Knauf</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Valet</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Borchi</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Nediani</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gharib</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ovize</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Delisle</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parini</surname><given-names>A</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Mialet-Perez</surname><given-names>J</given-names></name></person-group>
<article-title>p53-PGC-1alpha pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice</article-title>. <source/>Antioxid Redox Signal
<volume>18</volume>: <fpage>5</fpage>–<lpage>18</lpage>, <year>2013</year><pub-id pub-id-type="pmid">22738191</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Leitner</surname><given-names>EC</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Klinke</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Atzler</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Slocum</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lund</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kielstein</surname><given-names>JT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Maas</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt-Haupt</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pekarova</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hellwinkel</surname><given-names>O</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Tsikas</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>D'Alecy</surname><given-names>LG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lau</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Willems</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kubala</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ehmke</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Meinertz</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Blankenberg</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schwedhelm</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gadegbeku</surname><given-names>CA</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Boger</surname><given-names>RH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Baldus</surname><given-names>S</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Sydow</surname><given-names>K</given-names></name></person-group>
<article-title>Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase</article-title>. <source/>Circulation
<volume>124</volume>: <fpage>2735</fpage>–<lpage>2745</lpage>, <year>2011</year><pub-id pub-id-type="pmid">22082678</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Rosenke</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mika</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Khadzhynov</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loof</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neumayer</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Peters</surname><given-names>H</given-names></name></person-group>
<article-title>Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction</article-title>. <source/>J Urol
<volume>186</volume>: <fpage>1142</fpage>–<lpage>1149</lpage>, <year>2011</year><pub-id pub-id-type="pmid">21784461</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Rosenke</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Mika</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Khadzhynov</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Loof</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neumayer</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Peters</surname><given-names>H</given-names></name></person-group>
<article-title>Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction</article-title>. <source/>J Urol
<volume>188</volume>: <fpage>316</fpage>–<lpage>323</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22608751</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisskopf</surname><given-names>MG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>O'Reilly</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schwarzschild</surname><given-names>MA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A</given-names></name></person-group>
<article-title>Plasma urate and risk of Parkinson's disease</article-title>. <source/>Am J Epidemiol
<volume>166</volume>: <fpage>561</fpage>–<lpage>567</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17584757</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitzdoerfer</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hoeger</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Engidawork</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>M</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Singewald</surname><given-names>N</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Lubec</surname><given-names>G</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Lubec</surname><given-names>B</given-names></name></person-group>
<article-title>Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance</article-title>. <source/>Nitric Oxide
<volume>10</volume>: <fpage>130</fpage>–<lpage>140</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15158692</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whibley</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Urquhart</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Dore</surname><given-names>J</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Willatt</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Parkin</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Gaunt</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Black</surname><given-names>G</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Donnai</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Raymond</surname><given-names>FL</given-names></name></person-group>
<article-title>Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements</article-title>. <source/>Eur J Hum Genet
<volume>18</volume>: <fpage>1095</fpage>–<lpage>1099</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20485326</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson-Berka</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Deliyanti</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Rana</surname><given-names>I</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Miller</surname><given-names>AG</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Agrotis</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Armani</surname><given-names>R</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Szyndralewiez</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Jandeleit-Dahm</surname><given-names>KA</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy</article-title>. <source/>Antioxid Redox Signal
<volume>20</volume>: <fpage>2726</fpage>–<lpage>2740</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24053718</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wind</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beuerlein</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Armitage</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Taye</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Kumar</surname><given-names>AH</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Janowitz</surname><given-names>D</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Neff</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shah</surname><given-names>AM</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>
<article-title>Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition</article-title>. <source/>Hypertension
<volume>56</volume>: <fpage>490</fpage>–<lpage>497</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20606112</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wind</surname><given-names>S</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Beuerlein</surname><given-names>K</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Eucker</surname><given-names>T</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Muller</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Scheurer</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Armitage</surname><given-names>ME</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Ho</surname><given-names>H</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>HH</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Wingler</surname><given-names>K</given-names></name></person-group>
<article-title>Comparative pharmacology of chemically distinct NADPH oxidase inhibitors</article-title>. <source/>Br J Pharmacol
<volume>161</volume>: <fpage>885</fpage>–<lpage>898</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20860666</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Kettle</surname><given-names>AJ</given-names></name></person-group>
<article-title>Biomarkers of myeloperoxidase-derived hypochlorous acid</article-title>. <source/>Free Radic Biol Med
<volume>29</volume>: <fpage>403</fpage>–<lpage>409</lpage>, <year>2000</year><pub-id pub-id-type="pmid">11020661</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal">This reference has been deleted.</mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shao</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Hu</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Chen</surname><given-names>YT</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Yin</surname><given-names>F</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Liao</surname><given-names>CP</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Stiles</surname><given-names>BL</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Zhau</surname><given-names>HE</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shih</surname><given-names>JC</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Chung</surname><given-names>LW</given-names></name></person-group>
<article-title>Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis</article-title>. <source/>J Clin Invest
<volume>124</volume>: <fpage>2891</fpage>–<lpage>2908</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24865426</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name></person-group> and <person-group person-group-type="author"><name><surname>Zweier</surname><given-names>JL</given-names></name></person-group>
<article-title>Direct measurement of nitric oxide generation from nitric oxide synthase</article-title>. <source/>Proc Natl Acad Sci U S A
<volume>94</volume>: <fpage>12705</fpage>–<lpage>12710</lpage>, <year>1997</year><pub-id pub-id-type="pmid">9356514</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>MB</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Edmondson</surname><given-names>D</given-names></name></person-group>, and <person-group person-group-type="author"><name><surname>Tipton</surname><given-names>KF</given-names></name></person-group>
<article-title>The therapeutic potential of monoamine oxidase inhibitors</article-title>. <source/>Nat Rev Neurosci
<volume>7</volume>: <fpage>295</fpage>–<lpage>309</lpage>, <year>2006</year><pub-id pub-id-type="pmid">16552415</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<title>Abbreviations Used</title>
<def-list>
<def-item>
<term id="G1">ADMA</term>
<def>
<p>asymmetric dimethyl-<sc>l</sc>-arginine</p>
</def>
</def-item>
<def-item>
<term id="G2">apo-sGC</term>
<def>
<p>heme-free soluble guanylate cyclase</p>
</def>
</def-item>
<def-item>
<term id="G3">H<sub>4</sub>B</term>
<def>
<p>tetrahydrobiopetrin</p>
</def>
</def-item>
<def-item>
<term id="G4">cGMP</term>
<def>
<p>nicotinamide adenine dinucleotide phosphate</p>
</def>
</def-item>
<def-item>
<term id="G5">CVD</term>
<def>
<p>cardiovascular disease</p>
</def>
</def-item>
<def-item>
<term id="G6">CGD</term>
<def>
<p>chronic granulomatous disease</p>
</def>
</def-item>
<def-item>
<term id="G7">DUOX</term>
<def>
<p>dual oxidase</p>
</def>
</def-item>
<def-item>
<term id="G8">eNOS</term>
<def>
<p>endothelial nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term id="G9">FAD</term>
<def>
<p>flavin adenine dinucleotide</p>
</def>
</def-item>
<def-item>
<term id="G10">H<sub>2</sub>O<sub>2</sub></term>
<def>
<p>hydrogen peroxide</p>
</def>
</def-item>
<def-item>
<term id="G11">IC<sub>50</sub></term>
<def>
<p>half-maximal inhibitory concentration</p>
</def>
</def-item>
<def-item>
<term id="G12">iNOS</term>
<def>
<p>inducible nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term id="G13">
<italic>K<sub>m</sub></italic>
</term>
<def>
<p>Michaelis constant</p>
</def>
</def-item>
<def-item>
<term id="G14">KO</term>
<def>
<p>knockout</p>
</def>
</def-item>
<def-item>
<term id="G15">LPO</term>
<def>
<p>lipid peroxidase</p>
</def>
</def-item>
<def-item>
<term id="G16">MAO</term>
<def>
<p>monoamine oxidases</p>
</def>
</def-item>
<def-item>
<term id="G17">MPO</term>
<def>
<p>myeloperoxidase</p>
</def>
</def-item>
<def-item>
<term id="G18">NAD</term>
<def>
<p>nicotinamide adenine dinucleotide</p>
</def>
</def-item>
<def-item>
<term id="G19">NADPH</term>
<def>
<p>nicotinamide adenine dinucleotide phosphate</p>
</def>
</def-item>
<def-item>
<term id="G20">H<sub>4</sub>N</term>
<def>
<p>tetrahydroneopterin</p>
</def>
</def-item>
<def-item>
<term id="G21">nNOS</term>
<def>
<p>neuronal nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term id="G22">NO</term>
<def>
<p>nitric oxide</p>
</def>
</def-item>
<def-item>
<term id="G23">NOS</term>
<def>
<p>nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term id="G24">NOS1</term>
<def>
<p>nitric oxide synthase 1</p>
</def>
</def-item>
<def-item>
<term id="G25">NOS2</term>
<def>
<p>nitric oxide synthase 2</p>
</def>
</def-item>
<def-item>
<term id="G26">NOX</term>
<def>
<p>nicotinamide adenine dinucleotide phosphate oxidases</p>
</def>
</def-item>
<def-item>
<term id="G27">Nrf2</term>
<def>
<p>nuclear factor (erythroid-derived 2)-like 2</p>
</def>
</def-item>
<def-item>
<term id="G28">O<sub>2</sub><sup>−</sup></term>
<def>
<p>superoxide anion</p>
</def>
</def-item>
<def-item>
<term id="G29">PAH</term>
<def>
<p>pulmonary arterial hypertension</p>
</def>
</def-item>
<def-item>
<term id="G30">ROS</term>
<def>
<p>reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term id="G31">sGC</term>
<def>
<p>soluble guanylate cyclase</p>
</def>
</def-item>
<def-item>
<term id="G32">sGCa</term>
<def>
<p>soluble guanylate cyclase activators</p>
</def>
</def-item>
<def-item>
<term id="G33">sGCs</term>
<def>
<p>soluble guanylate cyclase stimulators</p>
</def>
</def-item>
<def-item>
<term id="G34">uc-eNOS</term>
<def>
<p>uncoupled endothelial nitric oxide synthase</p>
</def>
</def-item>
<def-item>
<term id="G35">XO</term>
<def>
<p>xanthine oxidase</p>
</def>
</def-item>
<def-item>
<term id="G36">XOi</term>
<def>
<p>xanthine oxidase inhibitors</p>
</def>
</def-item>
<def-item>
<term id="G37">XDH</term>
<def>
<p>xanthine dehydrogenase</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>